

Form 5500

Annual Return/Report of Employee Benefit Plan

OMB Nos. 1210-0110 1210-0089

2024

This Form is Open to Public Inspection

Department of the Treasury Internal Revenue Service

Department of Labor Employee Benefits Security Administration

Pension Benefit Guaranty Corporation

This form is required to be filed for employee benefit plans under sections 104 and 4065 of the Employee Retirement Income Security Act of 1974 (ERISA) and sections 6057(b) and 6058(a) of the Internal Revenue Code (the Code).

Complete all entries in accordance with the instructions to the Form 5500.

Part I Annual Report Identification Information

For calendar plan year 2024 or fiscal plan year beginning 01/01/2024 and ending 12/31/2024

- A This return/report is for: [ ] a multiemployer plan [ ] a multiple-employer plan (Filers checking this box must provide participating employer information in accordance with the form instructions.) [x] a single-employer plan [ ] a DFE (specify) \_\_\_\_
B This return/report is: [ ] the first return/report [ ] the final return/report [ ] an amended return/report [ ] a short plan year return/report (less than 12 months)
C If the plan is a collectively-bargained plan, check here. [ ]
D Check box if filing under: [x] Form 5558 [ ] automatic extension [ ] the DFVC program [ ] special extension (enter description)
E If this is a retroactively adopted plan permitted by SECURE Act section 201, check here. [ ]

Part II Basic Plan Information—enter all requested information

1a Name of plan AMERICAN SOCIETY OF CLINICAL ONCOLOGY 401(K) PROFIT SHARING PLAN
1b Three-digit plan number (PN) 001
1c Effective date of plan 01/01/1997
2a Plan sponsor's name (employer, if for a single-employer plan) Mailing address (include room, apt., suite no. and street, or P.O. Box) City or town, state or province, country, and ZIP or foreign postal code (if foreign, see instructions) AMERICAN SOCIETY OF CLINICAL ONCOLOGY 2318 MILL ROAD SUITE 800 ALEXANDRIA, VA 22314
2b Employer Identification Number (EIN) 13-6180380
2c Plan Sponsor's telephone number 571-483-1464
2d Business code (see instructions) 813000

Caution: A penalty for the late or incomplete filing of this return/report will be assessed unless reasonable cause is established.

Under penalties of perjury and other penalties set forth in the instructions, I declare that I have examined this return/report, including accompanying schedules, statements and attachments, as well as the electronic version of this return/report, and to the best of my knowledge and belief, it is true, correct, and complete.

Table with 4 columns: SIGN HERE, Signature of plan administrator, Date, Enter name of individual signing as plan administrator. Includes rows for employer/plan sponsor and DFE.

For Paperwork Reduction Act Notice, see the Instructions for Form 5500.

Form 5500 (2024) v. 240311

<b>3a</b> Plan administrator's name and address <input checked="" type="checkbox"/> Same as Plan Sponsor	<b>3b</b> Administrator's EIN	
	<b>3c</b> Administrator's telephone number	
<b>4</b> If the name and/or EIN of the plan sponsor or the plan name has changed since the last return/report filed for this plan, enter the plan sponsor's name, EIN, the plan name and the plan number from the last return/report: <b>a</b> Sponsor's name <b>c</b> Plan Name	<b>4b</b> EIN	
	<b>4d</b> PN	
<b>5</b> Total number of participants at the beginning of the plan year	<b>5</b>	794
<b>6</b> Number of participants as of the end of the plan year unless otherwise stated (welfare plans complete only lines <b>6a(1)</b> , <b>6a(2)</b> , <b>6b</b> , <b>6c</b> , and <b>6d</b> ). <b>a(1)</b> Total number of active participants at the beginning of the plan year ..... <b>a(2)</b> Total number of active participants at the end of the plan year ..... <b>b</b> Retired or separated participants receiving benefits..... <b>c</b> Other retired or separated participants entitled to future benefits ..... <b>d</b> Subtotal. Add lines <b>6a(2)</b> , <b>6b</b> , and <b>6c</b> ..... <b>e</b> Deceased participants whose beneficiaries are receiving or are entitled to receive benefits. .... <b>f</b> Total. Add lines <b>6d</b> and <b>6e</b> ..... <b>g(1)</b> Number of participants with account balances as of the beginning of the plan year (only defined contribution plans complete this item) ..... <b>g(2)</b> Number of participants with account balances as of the end of the plan year (only defined contribution plans complete this item) ..... <b>h</b> Number of participants who terminated employment during the plan year with accrued benefits that were less than 100% vested.....	<b>6a(1)</b>	438
	<b>6a(2)</b>	446
	<b>6b</b>	5
	<b>6c</b>	357
	<b>6d</b>	808
	<b>6e</b>	0
	<b>6f</b>	808
	<b>6g(1)</b>	791
<b>6g(2)</b>	803	
<b>6h</b>	26	
<b>7</b> Enter the total number of employers obligated to contribute to the plan (only multiemployer plans complete this item) .....	<b>7</b>	

**8a** If the plan provides pension benefits, enter the applicable pension feature codes from the List of Plan Characteristics Codes in the instructions:  
2G 2F 2J 2T 2E 3D

**b** If the plan provides welfare benefits, enter the applicable welfare feature codes from the List of Plan Characteristics Codes in the instructions:

<b>9a</b> Plan funding arrangement (check all that apply)	<b>9b</b> Plan benefit arrangement (check all that apply)
(1) <input type="checkbox"/> Insurance	(1) <input type="checkbox"/> Insurance
(2) <input type="checkbox"/> Code section 412(e)(3) insurance contracts	(2) <input type="checkbox"/> Code section 412(e)(3) insurance contracts
(3) <input checked="" type="checkbox"/> Trust	(3) <input checked="" type="checkbox"/> Trust
(4) <input type="checkbox"/> General assets of the sponsor	(4) <input type="checkbox"/> General assets of the sponsor

**10** Check all applicable boxes in 10a and 10b to indicate which schedules are attached, and, where indicated, enter the number attached. (See instructions)

<b>a Pension Schedules</b>	<b>b General Schedules</b>
(1) <input checked="" type="checkbox"/> <b>R</b> (Retirement Plan Information)	(1) <input checked="" type="checkbox"/> <b>H</b> (Financial Information)
(2) <input type="checkbox"/> <b>MB</b> (Multiemployer Defined Benefit Plan and Certain Money Purchase Plan Actuarial Information) - signed by the plan actuary	(2) <input type="checkbox"/> <b>I</b> (Financial Information – Small Plan)
(3) <input type="checkbox"/> <b>SB</b> (Single-Employer Defined Benefit Plan Actuarial Information) - signed by the plan actuary	(3) <input type="checkbox"/> <b>A</b> (Insurance Information) – Number Attached <u>0</u>
(4) <input type="checkbox"/> <b>DCG</b> (Individual Plan Information) – Number Attached _____	(4) <input checked="" type="checkbox"/> <b>C</b> (Service Provider Information)
(5) <input type="checkbox"/> <b>MEP</b> (Multiple-Employer Retirement Plan Information)	(5) <input checked="" type="checkbox"/> <b>D</b> (DFE/Participating Plan Information)
	(6) <input type="checkbox"/> <b>G</b> (Financial Transaction Schedules)

---

**Part III Form M-1 Compliance Information (to be completed by welfare benefit plans)**

---

**11a** If the plan provides welfare benefits, was the plan subject to the Form M-1 filing requirements during the plan year? (See instructions and 29 CFR 2520.101-2.) .....  Yes  No

If "Yes" is checked, complete lines 11b and 11c.

---

**11b** Is the plan currently in compliance with the Form M-1 filing requirements? (See instructions and 29 CFR 2520.101-2.) .....  Yes  No

**11c** Enter the Receipt Confirmation Code for the 2024 Form M-1 annual report. If the plan was not required to file the 2024 Form M-1 annual report, enter the Receipt Confirmation Code for the most recent Form M-1 that was required to be filed under the Form M-1 filing requirements. (Failure to enter a valid Receipt Confirmation Code will subject the Form 5500 filing to rejection as incomplete.)

Receipt Confirmation Code \_\_\_\_\_

---

<b>SCHEDULE C</b> <b>(Form 5500)</b>  <small>Department of the Treasury Internal Revenue Service</small>  <small>Department of Labor Employee Benefits Security Administration</small>  <small>Pension Benefit Guaranty Corporation</small>	<b>Service Provider Information</b>  This schedule is required to be filed under section 104 of the Employee Retirement Income Security Act of 1974 (ERISA).  <b>▶ File as an attachment to Form 5500.</b>	<small>OMB No. 1210-0110</small>  <b>2024</b>  <b>This Form is Open to Public Inspection.</b>
--	--	---

For calendar plan year 2024 or fiscal plan year beginning **01/01/2024** and ending **12/31/2024**

<b>A</b> Name of plan <b>AMERICAN SOCIETY OF CLINICAL ONCOLOGY 401(K) PROFIT SHARING PLAN</b>	<b>B</b> Three-digit plan number (PN) ▶	<b>001</b>
<b>C</b> Plan sponsor's name as shown on line 2a of Form 5500 <b>AMERICAN SOCIETY OF CLINICAL ONCOLOGY</b>	<b>D</b> Employer Identification Number (EIN) <b>13-6180380</b>	

**Part I Service Provider Information (see instructions)**

You must complete this Part, in accordance with the instructions, to report the information required for **each person** who received, directly or indirectly, \$5,000 or more in total compensation (i.e., money or anything else of monetary value) in connection with services rendered to the plan or the person's position with the plan during the plan year. If a person received **only** eligible indirect compensation for which the plan received the required disclosures, you are required to answer line 1 but are not required to include that person when completing the remainder of this Part.

**1 Information on Persons Receiving Only Eligible Indirect Compensation**

**a** Check "Yes" or "No" to indicate whether you are excluding a person from the remainder of this Part because they received only eligible indirect compensation for which the plan received the required disclosures (see instructions for definitions and conditions).....  Yes  No

**b** If you answered line 1a "Yes," enter the name and EIN or address of each person providing the required disclosures for the service providers who received only eligible indirect compensation. Complete as many entries as needed (see instructions).

**(b)** Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

**FIDELITY INVESTMENTS INSTITUTIONAL**

**04-2647786**

**(b)** Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

**(b)** Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

**(b)** Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

---

---

**(b)** Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

---

---

---

**(b)** Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

---

---

---

**(b)** Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

---

---

---

**(b)** Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

---

---

---

**(b)** Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

---

---

---

**(b)** Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

---

---

---

**(b)** Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

---

---

---

**(b)** Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

---

**2. Information on Other Service Providers Receiving Direct or Indirect Compensation.** Except for those persons for whom you answered "Yes" to line 1a above, complete as many entries as needed to list each person receiving, directly or indirectly, \$5,000 or more in total compensation (i.e., money or anything else of value) in connection with services rendered to the plan or their position with the plan during the plan year. (See instructions).

(a) Enter name and EIN or address (see instructions)

FIDELITY INVESTMENTS INSTITUTIONAL

04-2647786

(b) Service Code(s)	(c) Relationship to employer, employee organization, or person known to be a party-in-interest	(d) Enter direct compensation paid by the plan. If none, enter -0-.	(e) Did service provider receive indirect compensation? (sources other than plan or plan sponsor)	(f) Did indirect compensation include eligible indirect compensation, for which the plan received the required disclosures?	(g) Enter total indirect compensation received by service provider excluding eligible indirect compensation for which you answered "Yes" to element (f). If none, enter -0-.	(h) Did the service provider give you a formula instead of an amount or estimated amount?
64 65	RECORDKEEPER	58594	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>	0	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>

(a) Enter name and EIN or address (see instructions)

GLOBAL RETIREMENT PARTNERS, LLC

47-1411118

(b) Service Code(s)	(c) Relationship to employer, employee organization, or person known to be a party-in-interest	(d) Enter direct compensation paid by the plan. If none, enter -0-.	(e) Did service provider receive indirect compensation? (sources other than plan or plan sponsor)	(f) Did indirect compensation include eligible indirect compensation, for which the plan received the required disclosures?	(g) Enter total indirect compensation received by service provider excluding eligible indirect compensation for which you answered "Yes" to element (f). If none, enter -0-.	(h) Did the service provider give you a formula instead of an amount or estimated amount?
27	INVESTMENT ADVISOR	30000	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>		Yes <input type="checkbox"/> No <input type="checkbox"/>

(a) Enter name and EIN or address (see instructions)

(b) Service Code(s)	(c) Relationship to employer, employee organization, or person known to be a party-in-interest	(d) Enter direct compensation paid by the plan. If none, enter -0-.	(e) Did service provider receive indirect compensation? (sources other than plan or plan sponsor)	(f) Did indirect compensation include eligible indirect compensation, for which the plan received the required disclosures?	(g) Enter total indirect compensation received by service provider excluding eligible indirect compensation for which you answered "Yes" to element (f). If none, enter -0-.	(h) Did the service provider give you a formula instead of an amount or estimated amount?
			Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>		Yes <input type="checkbox"/> No <input type="checkbox"/>

**Part I Service Provider Information (continued)**

3. If you reported on line 2 receipt of indirect compensation, other than eligible indirect compensation, by a service provider, and the service provider is a fiduciary or provides contract administrator, consulting, custodial, investment advisory, investment management, broker, or recordkeeping services, answer the following questions for (a) each source from whom the service provider received \$1,000 or more in indirect compensation and (b) each source for whom the service provider gave you a formula used to determine the indirect compensation instead of an amount or estimated amount of the indirect compensation. Complete as many entries as needed to report the required information for each source.

<b>(a)</b> Enter service provider name as it appears on line 2	<b>(b)</b> Service Codes (see instructions)	<b>(c)</b> Enter amount of indirect compensation
<b>(d)</b> Enter name and EIN (address) of source of indirect compensation	<b>(e)</b> Describe the indirect compensation, including any formula used to determine the service provider's eligibility for or the amount of the indirect compensation.	
<b>(a)</b> Enter service provider name as it appears on line 2	<b>(b)</b> Service Codes (see instructions)	<b>(c)</b> Enter amount of indirect compensation
<b>(d)</b> Enter name and EIN (address) of source of indirect compensation	<b>(e)</b> Describe the indirect compensation, including any formula used to determine the service provider's eligibility for or the amount of the indirect compensation.	
<b>(a)</b> Enter service provider name as it appears on line 2	<b>(b)</b> Service Codes (see instructions)	<b>(c)</b> Enter amount of indirect compensation
<b>(d)</b> Enter name and EIN (address) of source of indirect compensation	<b>(e)</b> Describe the indirect compensation, including any formula used to determine the service provider's eligibility for or the amount of the indirect compensation.	

**Part II Service Providers Who Fail or Refuse to Provide Information**

**4** Provide, to the extent possible, the following information for each service provider who failed or refused to provide the information necessary to complete this Schedule.

<b>(a)</b> Enter name and EIN or address of service provider (see instructions)	<b>(b)</b> Nature of Service Code(s)	<b>(c)</b> Describe the information that the service provider failed or refused to provide

<b>(a)</b> Enter name and EIN or address of service provider (see instructions)	<b>(b)</b> Nature of Service Code(s)	<b>(c)</b> Describe the information that the service provider failed or refused to provide

<b>(a)</b> Enter name and EIN or address of service provider (see instructions)	<b>(b)</b> Nature of Service Code(s)	<b>(c)</b> Describe the information that the service provider failed or refused to provide

<b>(a)</b> Enter name and EIN or address of service provider (see instructions)	<b>(b)</b> Nature of Service Code(s)	<b>(c)</b> Describe the information that the service provider failed or refused to provide

<b>(a)</b> Enter name and EIN or address of service provider (see instructions)	<b>(b)</b> Nature of Service Code(s)	<b>(c)</b> Describe the information that the service provider failed or refused to provide

<b>(a)</b> Enter name and EIN or address of service provider (see instructions)	<b>(b)</b> Nature of Service Code(s)	<b>(c)</b> Describe the information that the service provider failed or refused to provide

**Part III Termination Information on Accountants and Enrolled Actuaries (see instructions)**  
(complete as many entries as needed)

<b>a</b> Name:	<b>b</b> EIN:
<b>c</b> Position:	
<b>d</b> Address:	<b>e</b> Telephone:

Explanation:

<b>a</b> Name:	<b>b</b> EIN:
<b>c</b> Position:	
<b>d</b> Address:	<b>e</b> Telephone:

Explanation:

<b>a</b> Name:	<b>b</b> EIN:
<b>c</b> Position:	
<b>d</b> Address:	<b>e</b> Telephone:

Explanation:

<b>a</b> Name:	<b>b</b> EIN:
<b>c</b> Position:	
<b>d</b> Address:	<b>e</b> Telephone:

Explanation:

<b>a</b> Name:	<b>b</b> EIN:
<b>c</b> Position:	
<b>d</b> Address:	<b>e</b> Telephone:

Explanation:

<b>SCHEDULE D</b> <b>(Form 5500)</b>  <small>Department of the Treasury Internal Revenue Service</small>  <small>Department of Labor Employee Benefits Security Administration</small>	<b>DFE/Participating Plan Information</b>  This schedule is required to be filed under section 104 of the Employee Retirement Income Security Act of 1974 (ERISA).  <b>▶ File as an attachment to Form 5500.</b>	OMB No. 1210-0110  <hr/> <b>2024</b>  <b>This Form is Open to Public Inspection.</b>
---	--	--

For calendar plan year 2024 or fiscal plan year beginning 01/01/2024 and ending 12/31/2024

<b>A</b> Name of plan <u>AMERICAN SOCIETY OF CLINICAL ONCOLOGY 401(K) PROFIT SHARING PLAN</u>	<b>B</b> Three-digit plan number (PN)	<u>001</u>
<b>C</b> Plan or DFE sponsor's name as shown on line 2a of Form 5500 <u>AMERICAN SOCIETY OF CLINICAL ONCOLOGY</u>	<b>D</b> Employer Identification Number (EIN) <u>13-6180380</u>	

<b>Part I</b>	<b>Information on interests in MTIAs, CCTs, PSAs, and 103-12 IEs (to be completed by plans and DFEs)</b> (Complete as many entries as needed to report all interests in DFEs)
---------------	--

<b>a</b> Name of MTIA, CCT, PSA, or 103-12 IE: <u>FA STABLE VALUE I</u>		
<b>b</b> Name of sponsor of entity listed in (a): <u>FIDELITY MANAGEMENT TRUST COMPANY</u>		
<b>c</b> EIN-PN <u>04-3022712-026</u>	<b>d</b> Entity code <u>C</u>	<b>e</b> Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) <u>2421529</u>
<b>a</b> Name of MTIA, CCT, PSA, or 103-12 IE:		
<b>b</b> Name of sponsor of entity listed in (a):		
<b>c</b> EIN-PN	<b>d</b> Entity code	<b>e</b> Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)
<b>a</b> Name of MTIA, CCT, PSA, or 103-12 IE:		
<b>b</b> Name of sponsor of entity listed in (a):		
<b>c</b> EIN-PN	<b>d</b> Entity code	<b>e</b> Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)
<b>a</b> Name of MTIA, CCT, PSA, or 103-12 IE:		
<b>b</b> Name of sponsor of entity listed in (a):		
<b>c</b> EIN-PN	<b>d</b> Entity code	<b>e</b> Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)
<b>a</b> Name of MTIA, CCT, PSA, or 103-12 IE:		
<b>b</b> Name of sponsor of entity listed in (a):		
<b>c</b> EIN-PN	<b>d</b> Entity code	<b>e</b> Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)
<b>a</b> Name of MTIA, CCT, PSA, or 103-12 IE:		
<b>b</b> Name of sponsor of entity listed in (a):		
<b>c</b> EIN-PN	<b>d</b> Entity code	<b>e</b> Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)
<b>a</b> Name of MTIA, CCT, PSA, or 103-12 IE:		
<b>b</b> Name of sponsor of entity listed in (a):		
<b>c</b> EIN-PN	<b>d</b> Entity code	<b>e</b> Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)
<b>a</b> Name of MTIA, CCT, PSA, or 103-12 IE:		
<b>b</b> Name of sponsor of entity listed in (a):		
<b>c</b> EIN-PN	<b>d</b> Entity code	<b>e</b> Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)

**a** Name of MTIA, CCT, PSA, or 103-12 IE:

**b** Name of sponsor of entity listed in (a):

**c** EIN-PN

**d** Entity code

**e** Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)

**a** Name of MTIA, CCT, PSA, or 103-12 IE:

**b** Name of sponsor of entity listed in (a):

**c** EIN-PN

**d** Entity code

**e** Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)

**a** Name of MTIA, CCT, PSA, or 103-12 IE:

**b** Name of sponsor of entity listed in (a):

**c** EIN-PN

**d** Entity code

**e** Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)

**a** Name of MTIA, CCT, PSA, or 103-12 IE:

**b** Name of sponsor of entity listed in (a):

**c** EIN-PN

**d** Entity code

**e** Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)

**a** Name of MTIA, CCT, PSA, or 103-12 IE:

**b** Name of sponsor of entity listed in (a):

**c** EIN-PN

**d** Entity code

**e** Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)

**a** Name of MTIA, CCT, PSA, or 103-12 IE:

**b** Name of sponsor of entity listed in (a):

**c** EIN-PN

**d** Entity code

**e** Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)

**a** Name of MTIA, CCT, PSA, or 103-12 IE:

**b** Name of sponsor of entity listed in (a):

**c** EIN-PN

**d** Entity code

**e** Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)

**a** Name of MTIA, CCT, PSA, or 103-12 IE:

**b** Name of sponsor of entity listed in (a):

**c** EIN-PN

**d** Entity code

**e** Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)

**a** Name of MTIA, CCT, PSA, or 103-12 IE:

**b** Name of sponsor of entity listed in (a):

**c** EIN-PN

**d** Entity code

**e** Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)

**a** Name of MTIA, CCT, PSA, or 103-12 IE:

**b** Name of sponsor of entity listed in (a):

**c** EIN-PN

**d** Entity code

**e** Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)



<b>SCHEDULE H</b> <b>(Form 5500)</b>  <small>Department of the Treasury Internal Revenue Service</small>  <small>Department of Labor Employee Benefits Security Administration</small>  <small>Pension Benefit Guaranty Corporation</small>	<b>Financial Information</b>  This schedule is required to be filed under section 104 of the Employee Retirement Income Security Act of 1974 (ERISA), and section 6058(a) of the Internal Revenue Code (the Code).  <b>▶ File as an attachment to Form 5500.</b>	<small>OMB No. 1210-0110</small>  <b>2024</b>  <b>This Form is Open to Public Inspection</b>
--	--	--

For calendar plan year 2024 or fiscal plan year beginning **01/01/2024** and ending **12/31/2024**

<b>A</b> Name of plan <b>AMERICAN SOCIETY OF CLINICAL ONCOLOGY 401(K) PROFIT SHARING PLAN</b>	<b>B</b> Three-digit plan number (PN)	<b>001</b>
<b>C</b> Plan sponsor's name as shown on line 2a of Form 5500 <b>AMERICAN SOCIETY OF CLINICAL ONCOLOGY</b>	<b>D</b> Employer Identification Number (EIN) <b>13-6180380</b>	

**Part I Asset and Liability Statement**

**1** Current value of plan assets and liabilities at the beginning and end of the plan year. Combine the value of plan assets held in more than one trust. Report the value of the plan's interest in a commingled fund containing the assets of more than one plan on a line-by-line basis unless the value is reportable on lines 1c(9) through 1c(14). Do not enter the value of that portion of an insurance contract which guarantees, during this plan year, to pay a specific dollar benefit at a future date. **Round off amounts to the nearest dollar.** MTIAs, CCTs, PSAs, and 103-12 IEs do not complete lines 1b(1), 1b(2), 1c(8), 1g, 1h, and 1i. CCTs, PSAs, and 103-12 IEs also do not complete lines 1d and 1e. See instructions.

Assets	(a) Beginning of Year	(b) End of Year
<b>a</b> Total noninterest-bearing cash .....	<b>1a</b> 0	0
<b>b</b> Receivables (less allowance for doubtful accounts):		
<b>(1)</b> Employer contributions .....	<b>1b(1)</b> 0	0
<b>(2)</b> Participant contributions .....	<b>1b(2)</b> 0	0
<b>(3)</b> Other .....	<b>1b(3)</b> 0	0
<b>c</b> General investments:		
<b>(1)</b> Interest-bearing cash (include money market accounts & certificates of deposit) .....	<b>1c(1)</b> 1205079	1326614
<b>(2)</b> U.S. Government securities .....	<b>1c(2)</b> 0	0
<b>(3)</b> Corporate debt instruments (other than employer securities):		
<b>(A)</b> Preferred .....	<b>1c(3)(A)</b> 0	0
<b>(B)</b> All other .....	<b>1c(3)(B)</b> 0	0
<b>(4)</b> Corporate stocks (other than employer securities):		
<b>(A)</b> Preferred .....	<b>1c(4)(A)</b> 0	0
<b>(B)</b> Common .....	<b>1c(4)(B)</b> 0	0
<b>(5)</b> Partnership/joint venture interests .....	<b>1c(5)</b> 0	0
<b>(6)</b> Real estate (other than employer real property) .....	<b>1c(6)</b> 0	0
<b>(7)</b> Loans (other than to participants) .....	<b>1c(7)</b> 0	0
<b>(8)</b> Participant loans .....	<b>1c(8)</b> 258133	98628
<b>(9)</b> Value of interest in common/collective trusts .....	<b>1c(9)</b> 2639803	2421529
<b>(10)</b> Value of interest in pooled separate accounts .....	<b>1c(10)</b> 0	0
<b>(11)</b> Value of interest in master trust investment accounts .....	<b>1c(11)</b> 0	0
<b>(12)</b> Value of interest in 103-12 investment entities .....	<b>1c(12)</b> 0	0
<b>(13)</b> Value of interest in registered investment companies (e.g., mutual funds) .....	<b>1c(13)</b> 107310616	119648854
<b>(14)</b> Value of funds held in insurance company general account (unallocated contracts) .....	<b>1c(14)</b> 0	0
<b>(15)</b> Other .....	<b>1c(15)</b> 0	0

1d Employer-related investments:		(a) Beginning of Year	(b) End of Year
(1) Employer securities.....	1d(1)	0	0
(2) Employer real property.....	1d(2)	0	0
e Buildings and other property used in plan operation.....	1e	0	0
f Total assets (add all amounts in lines 1a through 1e).....	1f	111413631	123495625
<b>Liabilities</b>			
g Benefit claims payable.....	1g	0	0
h Operating payables.....	1h	0	0
i Acquisition indebtedness.....	1i	0	0
j Other liabilities.....	1j	0	0
k Total liabilities (add all amounts in lines 1g through 1j).....	1k	0	0
<b>Net Assets</b>			
l Net assets (subtract line 1k from line 1f).....	1l	111413631	123495625

**Part II Income and Expense Statement**

2 Plan income, expenses, and changes in net assets for the year. Include all income and expenses of the plan, including any trust(s) or separately maintained fund(s) and any payments/receipts to/from insurance carriers. Round off amounts to the nearest dollar. MTIAs, CCTs, PSAs, and 103-12 IEs do not complete lines 2a, 2b(1)(E), 2e, 2f, and 2g.

Income		(a) Amount	(b) Total
<b>a Contributions:</b>			
(1) Received or receivable in cash from: (A) Employers.....	2a(1)(A)	4251556	
(B) Participants.....	2a(1)(B)	5330825	
(C) Others (including rollovers).....	2a(1)(C)	964236	
(2) Noncash contributions.....	2a(2)	0	
(3) Total contributions. Add lines 2a(1)(A), (B), (C), and line 2a(2).....	2a(3)		10546617
<b>b Earnings on investments:</b>			
(1) Interest:			
(A) Interest-bearing cash (including money market accounts and certificates of deposit).....	2b(1)(A)	55502	
(B) U.S. Government securities.....	2b(1)(B)	0	
(C) Corporate debt instruments.....	2b(1)(C)	0	
(D) Loans (other than to participants).....	2b(1)(D)	0	
(E) Participant loans.....	2b(1)(E)	10265	
(F) Other.....	2b(1)(F)	0	
(G) Total interest. Add lines 2b(1)(A) through (F).....	2b(1)(G)		65767
(2) Dividends:			
(A) Preferred stock.....	2b(2)(A)	0	
(B) Common stock.....	2b(2)(B)	0	
(C) Registered investment company shares (e.g. mutual funds).....	2b(2)(C)	3545492	
(D) Total dividends. Add lines 2b(2)(A), (B), and (C).....	2b(2)(D)		3545492
(3) Rents.....	2b(3)		0
(4) Net gain (loss) on sale of assets:			
(A) Aggregate proceeds.....	2b(4)(A)	0	
(B) Aggregate carrying amount (see instructions).....	2b(4)(B)	0	
(C) Subtract line 2b(4)(B) from line 2b(4)(A) and enter result.....	2b(4)(C)		
(5) Unrealized appreciation (depreciation) of assets:			
(A) Real estate.....	2b(5)(A)	0	
(B) Other.....	2b(5)(B)	0	
(C) Total unrealized appreciation of assets. Add lines 2b(5)(A) and (B).....	2b(5)(C)		

	(a) Amount	(b) Total
(6) Net investment gain (loss) from common/collective trusts .....	2b(6)	44569
(7) Net investment gain (loss) from pooled separate accounts .....	2b(7)	0
(8) Net investment gain (loss) from master trust investment accounts .....	2b(8)	0
(9) Net investment gain (loss) from 103-12 investment entities .....	2b(9)	0
(10) Net investment gain (loss) from registered investment companies (e.g., mutual funds) .....	2b(10)	12032125
<b>c</b> Other income .....	2c	0
<b>d</b> Total income. Add all <b>income</b> amounts in column (b) and enter total .....	2d	26234570

**Expenses**

<b>e</b> Benefit payment and payments to provide benefits:		
(1) Directly to participants or beneficiaries, including direct rollovers .....	2e(1)	14063982
(2) To insurance carriers for the provision of benefits .....	2e(2)	0
(3) Other .....	2e(3)	0
(4) Total benefit payments. Add lines 2e(1) through (3) .....	2e(4)	14063982
<b>f</b> Corrective distributions (see instructions) .....	2f	0
<b>g</b> Certain deemed distributions of participant loans (see instructions) .....	2g	0
<b>h</b> Interest expense .....	2h	0
<b>i</b> Administrative expenses:		
(1) Salaries and allowances .....	2i(1)	0
(2) Contract administrator fees .....	2i(2)	0
(3) Recordkeeping fees .....	2i(3)	58594
(4) IQPA audit fees .....	2i(4)	0
(5) Investment advisory and investment management fees .....	2i(5)	0
(6) Bank or trust company trustee/custodial fees .....	2i(6)	0
(7) Actuarial fees .....	2i(7)	0
(8) Legal fees .....	2i(8)	0
(9) Valuation/appraisal fees .....	2i(9)	0
(10) Other trustee fees and expenses .....	2i(10)	0
(11) Other expenses .....	2i(11)	30000
(12) Total administrative expenses. Add lines 2i(1) through (11) .....	2i(12)	88594
<b>j</b> Total expenses. Add all <b>expense</b> amounts in column (b) and enter total .....	2j	14152576

**Net Income and Reconciliation**

<b>k</b> Net income (loss). Subtract line 2j from line 2d .....	2k	12081994
<b>l</b> Transfers of assets:		
(1) To this plan .....	2l(1)	0
(2) From this plan .....	2l(2)	0

**Part III Accountant's Opinion**

**3** Complete lines 3a through 3c if the opinion of an independent qualified public accountant is attached to this Form 5500. Complete line 3d if an opinion is not attached.

**a** The attached opinion of an independent qualified public accountant for this plan is (see instructions):

(1)  Unmodified (2)  Qualified (3)  Disclaimer (4)  Adverse

**b** Check the appropriate box(es) to indicate whether the IQPA performed an ERISA section 103(a)(3)(C) audit. Check both boxes (1) and (2) if the audit was performed pursuant to both 29 CFR 2520.103-8 and 29 CFR 2520.103-12(d). Check box (3) if pursuant to neither.

(1)  DOL Regulation 2520.103-8 (2)  DOL Regulation 2520.103-12(d) (3)  neither DOL Regulation 2520.103-8 nor DOL Regulation 2520.103-12(d).

**c** Enter the name and EIN of the accountant (or accounting firm) below:

(1) Name: COHNREZNICK, LLP

(2) EIN: 33-4144829

**d** The opinion of an independent qualified public accountant is **not attached** as part of Schedule H because:

(1)  This form is filed for a CCT, PSA, DCG or MTIA. (2)  It will be attached to the next Form 5500 pursuant to 29 CFR 2520.104-50.

**Part IV Compliance Questions**

**4** CCTs and PSAs do not complete Part IV. MTIAs, 103-12 IEs, and GIAs do not complete lines 4a, 4e, 4f, 4g, 4h, 4k, 4m, 4n, or 5. 103-12 IEs also do not complete lines 4j and 4l. MTIAs also do not complete line 4l. DCGs do not complete lines 4e, 4f, 4k, 4l, and 5, and DCGs generally complete the rest of Part IV collectively for all plans in the DCG, except as otherwise provided (see instructions).

During the plan year:

**a** Was there a failure to transmit to the plan any participant contributions within the time period described in 29 CFR 2510.3-102? Continue to answer "Yes" for any prior year failures until fully corrected. (See instructions and DOL's Voluntary Fiduciary Correction Program.)

	Yes	No	Amount
<b>4a</b>	X		1235

**b** Were any loans by the plan or fixed income obligations due the plan in default as of the close of the plan year or classified during the year as uncollectible? Disregard participant loans secured by participant's account balance. (Attach Schedule G (Form 5500) Part I if "Yes" is checked.)

<b>4b</b>		X	
-----------	--	---	--

**c** Were any leases to which the plan was a party in default or classified during the year as uncollectible? (Attach Schedule G (Form 5500) Part II if "Yes" is checked.)

<b>4c</b>		X	
-----------	--	---	--

**d** Were there any nonexempt transactions with any party-in-interest? (Do not include transactions reported on line 4a. Attach Schedule G (Form 5500) Part III if "Yes" is checked.)

<b>4d</b>		X	
-----------	--	---	--

**e** Was this plan covered by a fidelity bond?

<b>4e</b>	X		1000000
-----------	---	--	---------

**f** Did the plan have a loss, whether or not reimbursed by the plan's fidelity bond, that was caused by fraud or dishonesty?

<b>4f</b>		X	
-----------	--	---	--

**g** Did the plan hold any assets whose current value was neither readily determinable on an established market nor set by an independent third party appraiser?

<b>4g</b>		X	
-----------	--	---	--

**h** Did the plan receive any noncash contributions whose value was neither readily determinable on an established market nor set by an independent third party appraiser?

<b>4h</b>		X	
-----------	--	---	--

**i** Did the plan have assets held for investment? (Attach schedule(s) of assets if "Yes" is checked, and see instructions for format requirements.)

<b>4i</b>	X		
-----------	---	--	--

**j** Were any plan transactions or series of transactions in excess of 5% of the current value of plan assets? (Attach schedule of transactions if "Yes" is checked and see instructions for format requirements.)

<b>4j</b>		X	
-----------	--	---	--

**k** Were all the plan assets either distributed to participants or beneficiaries, transferred to another plan, or brought under the control of the PBGC?

<b>4k</b>		X	
-----------	--	---	--

**l** Has the plan failed to provide any benefit when due under the plan?

<b>4l</b>		X	
-----------	--	---	--

**m** If this is an individual account plan, was there a blackout period? (See instructions and 29 CFR 2520.101-3.)

<b>4m</b>		X	
-----------	--	---	--

**n** If 4m was answered "Yes," check the "Yes" box if you either provided the required notice or one of the exceptions to providing the notice applied under 29 CFR 2520.101-3.

<b>4n</b>		X	
-----------	--	---	--

**5a** Has a resolution to terminate the plan been adopted during the plan year or any prior plan year?  Yes  No  
If "Yes," enter the amount of any plan assets that reverted to the employer this year \_\_\_\_\_.

**5b** If, during this plan year, any assets or liabilities were transferred from this plan to another plan(s), identify the plan(s) to which assets or liabilities were transferred. (See instructions.)

<b>5b(1)</b> Name of plan(s)	<b>5b(2)</b> EIN(s)	<b>5b(3)</b> PN(s)

**5c** Was the plan a defined benefit plan covered under the PBGC insurance program at any time during this plan year? (See ERISA section 4021 and instructions.) .....  Yes  No  Not determined

If "Yes" is checked, enter the My PAA confirmation number from the PBGC premium filing for this plan year \_\_\_\_\_.

<b>SCHEDULE R</b> <b>(Form 5500)</b>  <small>Department of the Treasury Internal Revenue Service</small>  <small>Department of Labor Employee Benefits Security Administration</small>  <small>Pension Benefit Guaranty Corporation</small>	<b>Retirement Plan Information</b>  This schedule is required to be filed under sections 104 and 4065 of the Employee Retirement Income Security Act of 1974 (ERISA) and section 6058(a) of the Internal Revenue Code (the Code).  <b>▶ File as an attachment to Form 5500.</b>	<small>OMB No. 1210-0110</small>  <b>2024</b>  <b>This Form is Open to Public Inspection.</b>
--	---	---

For calendar plan year 2024 or fiscal plan year beginning 01/01/2024 and ending 12/31/2024

<b>A</b> Name of plan <u>AMERICAN SOCIETY OF CLINICAL ONCOLOGY 401(K) PROFIT SHARING PLAN</u>	<b>B</b> Three-digit plan number (PN)	<u>001</u>
<b>C</b> Plan sponsor's name as shown on line 2a of Form 5500 <u>AMERICAN SOCIETY OF CLINICAL ONCOLOGY</u>	<b>D</b> Employer Identification Number (EIN) <u>13-6180380</u>	

<b>Part I</b>	<b>Distributions</b>
---------------	----------------------

**All references to distributions relate only to payments of benefits during the plan year.**

**1** Total value of distributions paid in property other than in cash or the forms of property specified in the instructions..... 1

**2** Enter the EIN(s) of payor(s) who paid benefits on behalf of the plan to participants or beneficiaries during the year (if more than two, enter EINs of the two payors who paid the greatest dollar amounts of benefits):  
 EIN(s): 04-6568107

**Profit-sharing plans, ESOPs, and stock bonus plans, skip line 3.**

**3** Number of participants (living or deceased) whose benefits were distributed in a single sum, during the plan year..... 3

<b>Part II</b>	<b>Funding Information</b> (If the plan is not subject to the minimum funding requirements of section 412 of the Internal Revenue Code or ERISA section 302, skip this Part.)
----------------	---

**4** Is the plan administrator making an election under Code section 412(d)(2) or ERISA section 302(d)(2)?.....  Yes  No  N/A  
**If the plan is a defined benefit plan, go to line 8.**

**5** If a waiver of the minimum funding standard for a prior year is being amortized in this plan year, see instructions and enter the date of the ruling letter granting the waiver. **Date:** Month \_\_\_\_\_ Day \_\_\_\_\_ Year \_\_\_\_\_  
**If you completed line 5, complete lines 3, 9, and 10 of Schedule MB and do not complete the remainder of this schedule.**

<b>6 a</b> Enter the minimum required contribution for this plan year (include any prior year accumulated funding deficiency not waived) .....	<b>6a</b>	
<b>b</b> Enter the amount contributed by the employer to the plan for this plan year .....	<b>6b</b>	
<b>c</b> Subtract the amount in line 6b from the amount in line 6a. Enter the result (enter a minus sign to the left of a negative amount).....	<b>6c</b>	

**If you completed line 6c, skip lines 8 and 9.**

**7** Will the minimum funding amount reported on line 6c be met by the funding deadline?.....  Yes  No  N/A

**8** If a change in actuarial cost method was made for this plan year pursuant to a revenue procedure or other authority providing automatic approval for the change or a class ruling letter, does the plan sponsor or plan administrator agree with the change?.....  Yes  No  N/A

<b>Part III</b>	<b>Amendments</b>
-----------------	-------------------

**9** If this is a defined benefit pension plan, were any amendments adopted during this plan year that increased or decreased the value of benefits? If yes, check the appropriate box. If no, check the "No" box.....  Increase  Decrease  Both  No

<b>Part IV</b>	<b>ESOPs</b> (see instructions). If this is not a plan described under section 409(a) or 4975(e)(7) of the Internal Revenue Code, skip this Part.
----------------	---

**10** Were unallocated employer securities or proceeds from the sale of unallocated securities used to repay any exempt loan?.....  Yes  No

**11 a** Does the ESOP hold any preferred stock?.....  Yes  No

**b** If the ESOP has an outstanding exempt loan with the employer as lender, is such loan part of a "back-to-back" loan? (See instructions for definition of "back-to-back" loan.).....  Yes  No

**12** Does the ESOP hold any stock that is not readily tradable on an established securities market?.....  Yes  No

**Part V Additional Information for Multiemployer Defined Benefit Pension Plans**

**13** Enter the following information for each employer that (1) contributed more than 5% of total contributions to the plan during the plan year or (2) was one of the top-ten highest contributors (measured in dollars). See instructions. Complete as many entries as needed to report all applicable employers.

**a** Name of contributing employer \_\_\_\_\_

**b** EIN \_\_\_\_\_ **c** Dollar amount contributed by employer \_\_\_\_\_

**d** Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box  and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month \_\_\_\_\_ Day \_\_\_\_\_ Year \_\_\_\_\_

**e** Contribution rate information (If more than one rate applies, check this box  and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) \_\_\_\_\_

(2) Base unit measure:  Hourly  Weekly  Unit of production  Other (specify): \_\_\_\_\_

**a** Name of contributing employer \_\_\_\_\_

**b** EIN \_\_\_\_\_ **c** Dollar amount contributed by employer \_\_\_\_\_

**d** Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box  and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month \_\_\_\_\_ Day \_\_\_\_\_ Year \_\_\_\_\_

**e** Contribution rate information (If more than one rate applies, check this box  and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) \_\_\_\_\_

(2) Base unit measure:  Hourly  Weekly  Unit of production  Other (specify): \_\_\_\_\_

**a** Name of contributing employer \_\_\_\_\_

**b** EIN \_\_\_\_\_ **c** Dollar amount contributed by employer \_\_\_\_\_

**d** Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box  and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month \_\_\_\_\_ Day \_\_\_\_\_ Year \_\_\_\_\_

**e** Contribution rate information (If more than one rate applies, check this box  and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) \_\_\_\_\_

(2) Base unit measure:  Hourly  Weekly  Unit of production  Other (specify): \_\_\_\_\_

**a** Name of contributing employer \_\_\_\_\_

**b** EIN \_\_\_\_\_ **c** Dollar amount contributed by employer \_\_\_\_\_

**d** Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box  and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month \_\_\_\_\_ Day \_\_\_\_\_ Year \_\_\_\_\_

**e** Contribution rate information (If more than one rate applies, check this box  and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) \_\_\_\_\_

(2) Base unit measure:  Hourly  Weekly  Unit of production  Other (specify): \_\_\_\_\_

**a** Name of contributing employer \_\_\_\_\_

**b** EIN \_\_\_\_\_ **c** Dollar amount contributed by employer \_\_\_\_\_

**d** Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box  and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month \_\_\_\_\_ Day \_\_\_\_\_ Year \_\_\_\_\_

**e** Contribution rate information (If more than one rate applies, check this box  and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) \_\_\_\_\_

(2) Base unit measure:  Hourly  Weekly  Unit of production  Other (specify): \_\_\_\_\_

**a** Name of contributing employer \_\_\_\_\_

**b** EIN \_\_\_\_\_ **c** Dollar amount contributed by employer \_\_\_\_\_

**d** Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box  and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month \_\_\_\_\_ Day \_\_\_\_\_ Year \_\_\_\_\_

**e** Contribution rate information (If more than one rate applies, check this box  and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) \_\_\_\_\_

(2) Base unit measure:  Hourly  Weekly  Unit of production  Other (specify): \_\_\_\_\_

**14** Enter the number of deferred vested and retired participants (inactive participants), as of the beginning of the plan year, whose contributing employer is no longer making contributions to the plan for:

<b>a</b> The current plan year. Check the box to indicate the counting method used to determine the number of inactive participants: <input type="checkbox"/> last contributing employer <input type="checkbox"/> alternative <input type="checkbox"/> reasonable approximation (see instructions for required attachment).....	<b>14a</b>	
<b>b</b> The plan year immediately preceding the current plan year. <input type="checkbox"/> Check the box if the number reported is a change from what was previously reported (see instructions for required attachment).....	<b>14b</b>	
<b>c</b> The second preceding plan year. <input type="checkbox"/> Check the box if the number reported is a change from what was previously reported (see instructions for required attachment).....	<b>14c</b>	

**15** Enter the ratio of the number of participants under the plan on whose behalf no employer had an obligation to make an employer contribution during the current plan year to:

<b>a</b> The corresponding number for the plan year immediately preceding the current plan year .....	<b>15a</b>	
<b>b</b> The corresponding number for the second preceding plan year .....	<b>15b</b>	

**16** Information with respect to any employers who withdrew from the plan during the preceding plan year:

<b>a</b> Enter the number of employers who withdrew during the preceding plan year .....	<b>16a</b>	
<b>b</b> If line 16a is greater than 0, enter the aggregate amount of withdrawal liability assessed or estimated to be assessed against such withdrawn employers.....	<b>16b</b>	

**17** If assets and liabilities from another plan have been transferred to or merged with this plan during the plan year, check box and see instructions regarding supplemental information to be included as an attachment .....

**Part VI Additional Information for Single-Employer and Multiemployer Defined Benefit Pension Plans**

**18** If any liabilities to participants or their beneficiaries under the plan as of the end of the plan year consist (in whole or in part) of liabilities to such participants and beneficiaries under two or more pension plans as of immediately before such plan year, check box and see instructions regarding supplemental information to be included as an attachment .....

**19** If the total number of participants is 1,000 or more, complete lines (a) and (b):

**a** Enter the percentage of plan assets held as:  
 Public Equity: \_\_\_\_\_% Private Equity: \_\_\_\_\_% Investment-Grade Debt and Interest Rate Hedging Assets: \_\_\_\_\_%  
 High-Yield Debt: \_\_\_\_\_% Real Assets: \_\_\_\_\_% Cash or Cash Equivalents: \_\_\_\_\_% Other: \_\_\_\_\_%

**b** Provide the average duration of the Investment-Grade Debt and Interest Rate Hedging Assets:  
 0-5 years  5-10 years  10-15 years  15 years or more

**20 PBGC missed contribution reporting requirements.** If this is a multiemployer plan or a single-employer plan that is not covered by PBGC, skip line 20.

**a** Is the amount of unpaid minimum required contributions for all years from Schedule SB (Form 5500) line 40 greater than zero?  Yes  No

**b** If line 20a is "Yes," has PBGC been notified as required by ERISA sections 4043(c)(5) and/or 303(k)(4)? Check the applicable box:  
 Yes.  
 No. Reporting was waived under 29 CFR 4043.25(c)(2) because contributions equal to or exceeding the unpaid minimum required contribution were made by the 30th day after the due date.  
 No. The 30-day period referenced in 29 CFR 4043.25(c)(2) has not yet ended, and the sponsor intends to make a contribution equal to or exceeding the unpaid minimum required contribution by the 30th day after the due date.  
 No. Other. Provide explanation: \_\_\_\_\_

**Part VII IRS Compliance Questions**

**21a** Does the plan satisfy the coverage and nondiscrimination tests of Code sections 410(b) and 401(a)(4) by combining this plan with any other plans under the permissive aggregation rules?  Yes  No

**21b** If this is a Code section 401(k) plan, check all boxes that apply to indicate how the plan is intended to satisfy the nondiscrimination requirements for employee deferrals and employer matching contributions (as applicable) under Code sections 401(k)(3) and 401(m)(2).  
 Design-based safe harbor method  
 "Prior year" ADP test  
 "Current year" ADP test  
 N/A

**22** If the plan sponsor is an adopter of a pre-approved plan that received a favorable IRS Opinion Letter, enter the date of the Opinion Letter 06 / 30 / 2020 (MM/DD/YYYY) and the Opinion Letter serial number Q702438A.

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

**Financial Statements  
(With Supplementary Information)  
and Independent Auditor's Report**

**December 31, 2024 and 2023**

---

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

Index

	<u>Page</u>
Independent Auditor's Report	2
Financial Statements	
Statements of Net Assets Available for Benefits	6
Statements of Changes in Net Assets Available for Benefits	7
Notes to Financial Statements	8
Supplementary Information	
Schedule of Delinquent Contributions (Schedule H, Line 4a)	16
Schedule of Assets (Held at End of Year) (Schedule H, Line 4i)	17

Independent Auditor's Report

To the Plan Administrator  
American Society of Clinical Oncology 401(k) Profit Sharing Plan

*Scope and Nature of the ERISA Section 103(a)(3)(C) Audit*

We have performed audits of the financial statements of American Society of Clinical Oncology 401(k) Profit Sharing Plan (the "Plan"), an employee benefit plan subject to the Employee Retirement Income Security Act of 1974 ("ERISA"), as permitted by ERISA Section 103(a)(3)(C). The financial statements comprise the statements of net assets available for benefits as of December 31, 2024 and 2023, and the related statements of changes in net assets available for benefits for the years then ended and the related notes to the financial statements.

Management, having determined it is permissible in the circumstances, has elected to have the audits of the Plan's financial statements performed in accordance with ERISA Section 103(a)(3)(C) pursuant to 29 CFR 2520.103-8 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA. As permitted by ERISA Section 103(a)(3)(C), our audit need not extend to any statements or information related to assets held for investment of the Plan ("investment information") by a bank or similar institution or insurance carrier that is regulated, supervised, and subject to periodic examination by a state or federal agency, provided that the statements or information regarding assets so held are prepared and certified to by the bank or similar institution or insurance carrier in accordance with 29 CFR 2520.103-5 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA ("qualified institution").

Management has obtained certifications from a qualified institution as of December 31, 2024 and 2023, and for the years ended December 31, 2024 and 2023, stating that the certified investment information, as described in Note 4 to the financial statements, is complete and accurate.

*Opinion*

In our opinion, based on our audits and on the procedures performed as described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section:

- The amounts and disclosures in the accompanying financial statements, other than those agreed to or derived from the certified investment information, are presented fairly, in all material respects, in accordance with accounting principles generally accepted in the United States of America.
- The information in the accompanying financial statements related to assets held by and certified to by a qualified institution agrees to, or is derived from, in all material respects, the information prepared and certified by an institution that management determined meets the requirements of ERISA Section 103(a)(3)(C).

### *Basis for Opinion*

We conducted our audits in accordance with auditing standards generally accepted in the United States of America ("GAAS"). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are required to be independent of the Plan and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our ERISA Section 103(a)(3)(C) audit opinion.

### *Responsibilities of Management for the Financial Statements*

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error. Management's election of the ERISA Section 103(a)(3)(C) audit does not affect management's responsibility for the financial statements.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Plan's ability to continue as a going concern for one year after the date that the financial statements are available to be issued.

Management is also responsible for maintaining a current Plan instrument, including all Plan amendments, administering the Plan, and determining that the Plan's transactions that are presented and disclosed in the financial statements are in conformity with the Plan's provisions, including maintaining sufficient records with respect to each of the participants, to determine the benefits due or which may become due to such participants.

### *Auditor's Responsibilities for the Audit of the Financial Statements*

Except as described in the *Scope and Nature of the ERISA Section 103(a)(3)(C) Audit* section of our report, our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a significant likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Plan's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Plan's ability to continue as a going concern for a reasonable period of time.

Our audits did not extend to the certified investment information, except for obtaining and reading the certification, comparing the certified investment information with the related information presented and disclosed in the financial statements, and reading the disclosures relating to the certified investment information to assess whether they are in accordance with the presentation and disclosure requirements of accounting principles generally accepted in the United States of America.

Accordingly, the objective of an ERISA Section 103(a)(3)(C) audit is not to express an opinion about whether the financial statements as a whole are presented fairly, in all material respects, in accordance with accounting principles generally accepted in the United States of America.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Other Matters

#### *Supplemental Schedules Required by ERISA*

The supplemental Schedule of Delinquent Contributions (Schedule H, Line 4a) for the year ended December 31, 2024, and the supplemental Schedule of Assets (Held at End of Year) (Schedule H, Line 4i) as of December 31, 2024, are presented for purposes of additional analysis and is not a required part of the financial statements but is supplementary information required by the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information included in the supplemental schedules, other than that agreed to or derived from the certified investment information, has been subjected to auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with GAAS. For information included in the supplemental schedules that agreed to or is derived from the certified investment information, we compared such information to the related certified investment information.

In forming our opinion on the supplemental schedules, we evaluated whether the supplemental schedules, other than the information agreed to or derived from the certified investment information, including their form and content, is presented in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA.

In our opinion:

- The form and content of the supplemental schedule, other than the information in the supplemental schedule that agreed to or is derived from the certified investment information, is presented, in all material respects, in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA.
- The information in the supplemental schedule related to assets held by and certified to by a qualified institution agrees to, or is derived from, in all material respects, the information prepared and certified by an institution that management determined meets the requirements of ERISA Section 103(a)(3)(C).

*CohnReznick LLP*

Bethesda, Maryland  
October 10, 2025

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

**Statements of Net Assets Available for Benefits  
December 31, 2024 and 2023**

	<u>2024</u>	<u>2023</u>
Assets		
Investments, at fair value	\$ 120,975,468	\$ 108,515,695
Investments, at contract value	<u>2,594,090</u>	<u>2,803,926</u>
Total investments	<u>123,569,558</u>	<u>111,319,621</u>
Receivables		
Notes receivable from participants	<u>98,628</u>	<u>258,133</u>
Total receivables	<u>98,628</u>	<u>258,133</u>
Net assets available for benefits	<u><u>\$ 123,668,186</u></u>	<u><u>\$ 111,577,754</u></u>

See Notes to Financial Statements.

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

**Statements of Changes in Net Assets Available for Benefits  
Years Ended December 31, 2024 and 2023**

	2024	2023
Additions		
Investment income		
Net appreciation in fair value of investments	\$ 12,085,130	\$ 14,764,618
Interest and dividend income	3,600,996	2,463,795
	15,686,126	17,228,413
Total investment income		
Interest income on notes receivable from participants	10,265	13,916
Contributions		
Participants	5,330,825	5,814,257
Employer	4,251,556	4,610,511
Rollovers	964,236	649,319
	10,546,617	11,074,087
Total contributions		
Total additions	26,243,008	28,316,416
Deductions		
Benefits paid to participants	14,063,982	8,817,031
Administrative expenses	88,594	122,239
	14,152,576	8,939,270
Total deductions		
Increase in net assets	12,090,432	19,377,146
Net assets available for benefits		
Beginning	111,577,754	92,200,608
End	\$ 123,668,186	\$ 111,577,754

See Notes to Financial Statements.

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

**Notes to Financial Statements  
December 31, 2024 and 2023**

**Note 1 - Description of Plan**

The following description of the American Society of Clinical Oncology 401(k) Profit Sharing Plan (the "Plan") provides only general information. Participants should refer to the Plan document and any amendments for more complete information.

**General**

The Plan is a defined contribution plan covering all eligible employees of the American Society of Clinical Oncology, Inc. (the "Society") and the ASCO Association (the "Association"), collectively, the "Organization". All employees are eligible to participate in the Plan upon hire and per the Plan are eligible to receive employer contributions at the start of the next calendar month of employment. However, for administrative purposes, employer contributions begin with the first paycheck. The 401(k) Plan Administrative Committee of the Society is responsible for the operation and administration of the Plan. Fidelity Management Trust Company ("Fidelity") serves as the trustee and record keeper of the Plan. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974 ("ERISA").

**Contributions**

The Plan provides for voluntary employee contributions between 1% and 90% of a participant's annual earnings up to the 401(k) contribution limit defined in the Internal Revenue Code (the "IRC"). Any contributions that exceed Internal Revenue Service (the "IRS") limitations are returned to the participant as a corrective distribution. Such amounts, if any, are netted against participant contributions in the financial statements. Participants may also contribute amounts representing distributions from other qualified defined benefit or defined contribution plans ("rollovers").

Participants direct the investment of their contributions into various investment options offered by the Plan. The Company makes safe harbor nonelective contributions equal to 3% of the employee's eligible wages. The Company also may make discretionary contributions of a fixed percentage of compensation for each participant. The discretionary contribution rate for each of the years ended December 31, 2024 and 2023 was 4.5%. During the years ended December 31, 2024 and 2023, the Company contributed nonelective contributions amounting to \$1,750,586 and \$1,885,877, respectively, and discretionary contributions amounting to \$2,500,970 and \$2,724,634, respectively.

**Participant accounts**

Each participant's account is credited with the participant's contributions, including amounts rolled over from other qualified plans, and allocation of (a) Organization's contributions, (b) Plan earnings (losses), and (c) administrative expenses (until March 23, 2022). Allocations are based on participant compensation or account balances or specific participant transactions, as defined. The benefit to which a participant is entitled is the benefit that can be provided from the participant's vested account.

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

**Notes to Financial Statements  
December 31, 2024 and 2023**

**Vesting**

Participants are immediately vested in all participant contributions and safe harbor nonelective employer contributions plus actual earnings thereon. Employees vest in the discretionary nonelective contributions in accordance with the following schedule:

<u>Years of Service</u>	<u>Vesting Percentage</u>
Less than 1 year	0%
1	25%
2	50%
3	75%
4	100%

**Forfeitures**

Forfeitures occur when an employee ends participation in the Plan prior to becoming fully vested in his/her discretionary portion of the account. These forfeited nonvested balances are used to reduce future employer contributions. Forfeitures of \$125,000 and \$104,197, respectively, were used to reduce employer contributions during the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024 and 2023, forfeited nonvested accounts totaled \$78,518 and \$25,849, respectively.

**Notes receivable from participants**

Participants may borrow from their investment accounts a hardship loan of a minimum of \$1,000 up to a maximum of \$50,000, or 50% of their vested account balance, whichever is less. Under the CARES Act, the maximum loan was increased to \$100,000 and the repayment period for loans was extended up to one year, if applicable. The notes are secured by the balance in the participant's account and bear interest at rates that range from 4.25% to 9.5%, which is commensurate with the average of the prime lending rates at the time the note is taken out by the participant. The notes are measured at their unpaid principal balance plus any accrued but unpaid interest. The notes are to be repaid by salary deductions over periods no longer than five years unless the proceeds are used to buy the participant's main residence. Under the Plan, if a participant ceases to make loan repayments and the Plan administrator deems the participant loan to be in default, the participant loan balance is reduced and a benefit payment is recorded.

**Payment of benefits**

Upon termination of service due to death, disability, retirement or any other reason, a participant or beneficiary may elect to receive either a lump sum amount equal to the value of the participant's vested interest in his or her account. Accounts with balances of \$5,000 or less are automatically distributed and rolled over into an individual retirement account established at Fidelity Management Trust Company. Lump sum distributions may be in the form of (i) paid directly to participant or beneficiary; (ii) direct rollover to qualified eligible plan or individual retirement account; and/or (iii) combination of direct payment or rollover. The participant may also receive partial withdrawal after termination of employment. The Plan also allows for hardship withdrawals in accordance with the terms of the Plan document.

**Administrative expenses**

Participant transaction charges incurred by participants are charged directly to their accounts. Plan administrative expenses are paid by the Society.

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

**Notes to Financial Statements  
December 31, 2024 and 2023**

**Income tax status**

The Plan operates under an adopted prototype non-standardized pre-approved profit sharing plan with a cash or deferral arrangement of FMR LLC (the "prototype plan") that most recently received a favorable opinion letter from the IRS on June 30, 2020, which stated that the prototype plan and related trust are designed in accordance with applicable sections of the IRC. While the Plan has been amended since adopting the prototype plan, the Society believes the Plan is currently being operated in accordance with the IRC.

Accounting principles generally accepted in the United States of America require Plan management to evaluate tax positions taken by the Plan and recognize a tax liability if the Plan has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress.

**Note 2 - Summary of accounting policies**

**Basis of accounting**

The Plan's financial statements are prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP").

**Use of estimates**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Plan's management to make estimates and assumptions that affect the reported amounts of assets and liabilities and changes therein, and disclosure of contingent assets and liabilities. Actual results could differ from those estimates.

**Investment valuation and income recognition**

Investments are reported at fair value. Shares of registered investment companies are valued at quoted market prices in an active market, which represent the net asset value of shares held by the Plan at year end. The Plan's direct investment in the fully benefit-responsive investment contract is reported at contract value.

The preceding methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date. Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded as earned. Dividends are recorded on the ex-dividend date. The Plan presents in the statements of changes in net assets available for benefits the net appreciation or (depreciation) in the fair value of its investments, which consists of the realized gains or losses and the unrealized appreciation or (depreciation) of those investments.

**Contributions**

Contributions from Plan participants and contributions from the Organization are recorded in the year in which the employee contributions are withheld from compensation.

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

**Notes to Financial Statements  
December 31, 2024 and 2023**

**Notes receivable from participants**

Notes receivable from participants are measured at the unpaid principal balances plus any accrued but unpaid interest. Interest income is recorded on the accrual basis. Related fees are recorded as administrative expenses and are expensed when they are incurred.

**Payment of benefits**

Benefits are recorded when paid.

**Reclassifications**

Certain items from the prior year financial statements have been reclassified to conform to the current year presentation.

**Note 3 - Plan termination**

Although it has not expressed any intent to do so, the Organization has the right to discontinue its contributions, amend, or terminate the Plan subject to the provisions of ERISA at any time without the consent of participants. If the Plan is terminated, the value of all employer contributions becomes immediately fully vested.

**Note 4 - Certified investments**

The Plan administrator has elected the method of compliance permitted by 29 CFR 2520.103-8 of the DOL's Rules and Regulations for Reporting and Disclosure under ERISA. Investments and notes receivable from participants held at December 31, 2024 and 2023, and investment income and interest income on notes receivable from participants for the years then ended, that is disclosed in the accompanying financial statements and supplemental schedule of assets (held at end of year) as of December 31, 2024 was obtained or derived from information supplied to the Plan administrator and certified as complete and accurate by Fidelity Management Trust Company, the trustee of the Plan.

**Note 5 - Fair value measurements**

The framework for measuring fair value provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities ("Level 1") and the lowest priority to unobservable inputs ("Level 3").

The three levels of the fair value hierarchy under U.S. GAAP are described as follows:

Level 1 - Observable inputs that reflect quoted prices for identical assets or liabilities in active markets, such as stock quotes.

Level 2 - Includes inputs other than Level 1 that are directly or indirectly observable in the marketplace, such as yield curves or other market data.

Level 3 - Unobservable inputs which reflect the reporting entity's assessment of the assumptions that market participants would use in pricing the asset or liability including assumptions about risk, such as bid/ask spreads and liquidity discounts.

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

**Notes to Financial Statements  
December 31, 2024 and 2023**

Following is a description of the valuation methodology used for assets measured at fair value. There have been no changes in the valuation methodology used at December 31, 2024 and 2023. This method may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Plan believes its valuation method is appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

*Mutual funds* - Valued at the daily closing price as reported by the fund. Mutual funds held by the Plan are open-end mutual funds that are registered with the Securities and Exchange Commission. These funds are required to publish their daily net asset value and to transact at that price. The mutual funds held by the Plan are deemed to be actively traded.

Investments, recorded at fair value and measured on a recurring basis, consist of the following at:

Assets at Fair Value as of December 31, 2024				
	Total	Level 1	Level 2	Level 3
Mutual funds	\$ 120,975,468	\$ 120,975,468	\$ -	\$ -
Assets at Fair Value as of December 31, 2023				
	Total	Level 1	Level 2	Level 3
Mutual funds	\$ 108,515,695	\$ 108,515,695	\$ -	\$ -

**Note 6 - Guaranteed Investment Contract with Fidelity Management Trust Company**

The Plan maintains a benefit-responsive investment contract with Fidelity titled the "Fidelity Advisor Stable Value Portfolio Class I" (the "Trust") amounting to \$2,594,090 and \$2,803,926 as of December 31, 2024 and 2023, respectively. The Trust invests primarily in synthetic investment contracts backed by high credit-quality fixed income investments and traditional investments issued by insurance companies and banks. The account is credited with earnings on the underlying investments, and charged for plan withdrawals and administrative expenses. Because the guaranteed investment contract is fully benefit-responsive, contract value is the relevant measurement attribute for that portion of the net assets available for benefits attributable to the guaranteed investment contract.

Contract value represents contributions made under the contract, plus earnings, less participant withdrawals and administrative expenses. Participants may ordinarily direct withdrawals or transfer all or a portion of their investment at contract value.

Certain events could limit the Plan's ability to transact at contract value with Plan participants. Such events include: (a) amendments to the Plan document (including complete or partial Plan termination or merger with another plan), (b) the operation of another investment option that is deemed to be competitive with the Trust, or (c) another pension plan is established in which Plan participants are eligible to contribute by payroll deductions. The Plan administrator does not believe that the occurrence of any of these events is probable.

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

**Notes to Financial Statements  
December 31, 2024 and 2023**

**Note 7 - Related party and party-in-interest transactions**

The guaranteed investment contract and many of the mutual funds offered as Plan investments are managed by Fidelity. Fidelity is the trustee as defined by the Plan and, therefore, these transactions qualify as party-in-interest transactions. As described in Note 1, the Plan received amounts from the excess of recordkeeping over plan expenses.

**Note 8 - Reconciliation of financial statements to Form 5500**

The following is a reconciliation of net assets available for benefits and additions per the financial statements to Form 5500 as of December 31, 2024 and 2023:

	2024	2023
Net assets available for plan benefits, financial statements	\$ 123,668,186	\$ 111,577,754
Adjustment from contract value to fair value for fully benefit-responsive investment contracts	(172,561)	(164,123)
Net assets available for plan benefits, Form 5500	\$ 123,495,625	\$ 111,413,631
	2024	2023
Total increase per the financial statements	\$ 12,090,432	\$ 19,377,146
2024 adjustment from contract value to fair value for fully benefit-responsive investments	(172,561)	-
2023 adjustment from contract value to fair value for fully benefit-responsive investments	164,123	(164,123)
2022 adjustment from contract value to fair value for fully benefit-responsive investments	-	222,560
Net income per Form 5500	\$ 12,081,994	\$ 19,435,583

**Note 9 - Risks and uncertainties**

The Plan invests in various investment securities. Investment securities are exposed to various risks, including interest rate, market and credit risks. Due to the level of risk associated with certain investment securities, it is possible that changes in the fair values of investment securities will occur in the near-term, and that such changes could materially affect participants' account balances and the amounts reported in the statements of net assets available for benefits.

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

**Notes to Financial Statements  
December 31, 2024 and 2023**

**Note 10 - Subsequent events**

Events that occur after the statement of net assets available for benefits date but before the financial statements were available to be issued must be evaluated for recognition or disclosure. The effects of subsequent events that provide evidence about conditions that existed at the statement of net assets available for benefits date are recognized in the accompanying financial statements. Subsequent events which provide evidence about conditions that existed after the statements of net assets available for benefits date require disclosure in the accompanying notes. Management evaluated the activity of the Plan through October 10, 2025 (the date the financial statements were available to be issued) and concluded that no subsequent events have occurred that would require recognition in the financial statements or disclosure is required in the notes to the financial statements.

**Note 11 - Nonexempt transactions**

As reported on the supplemental Schedule of Delinquent Contributions (Schedule H, Line 4a), \$1,235 of Plan participant contributions were not remitted to the trust within the time frame specified by the DOL's regulations 29 (CFR 2510.3-102), thus constituting nonexempt transactions between the Plan and the Organization relating to the 2015 Plan year that was discovered by Plan management during the 2024 Plan year. The late participant contribution of \$1,235 was paid into the plan on September 23, 2025. As of the date these Plan financial statements were available to be issued, Plan management was in the process of preparing an application to submit to the DOL's Voluntary Fiduciary Correction Program to complete the correction process.

## **Supplementary Information**

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan  
EIN: 13-6180380  
Plan # 001**

**Schedule of Delinquent Participant Contributions (Schedule H, Line 4a)  
Year end of December 31, 2024**

Year	Participant contributions transferred late to plan	Check here if participant loan repayments are included	Total that constitute nonexempt prohibited transactions			Total fully corrected under VFCP and Prohibited Transaction Exemption 2002-51
			Contributions not corrected	Contributions corrected outside the Voluntary Fiduciary Correction Program ("VFCP")	Contributions pending correction in VFCP	
2015	\$ 1,235		\$ 1,235	\$ -	\$ -	\$ -

See Independent Auditor's Report.

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan  
EIN: 13-6180380  
Plan # 001**

**Schedule of Assets (Held at End of Year) (Schedule H, Line 4i)  
December 31, 2024**

(a)	(b) Identity of issuer, borrower, lessor or similar party	(c) Description of Investment including Maturity Date, Rate of Interest, Collateral, Par or Maturity Value	(e) Current Value
Mutual funds:			
*	Fidelity® 500 Index Fund	Mutual Funds	\$ 15,263,154
*	Fidelity Advisor Freedom® 2040 Fund Class Z6	Mutual Funds	5,771,686
	BlackRock Equity Dividend Fund K Shares	Mutual Funds	4,764,533
*	Fidelity Advisor Freedom® 2050 Fund Class Z6	Mutual Funds	4,560,101
*	Fidelity Advisor Freedom® 2035 Fund Class Z6	Mutual Funds	6,535,708
	BlackRock LifePath® Index 2045 Fund Class K Shares	Mutual Funds	6,468,155
*	Fidelity Advisor Freedom® 2045 Fund Class Z6	Mutual Funds	4,948,140
	BlackRock LifePath® Index 2050 Fund Class K Shares	Mutual Funds	6,857,534
	BlackRock LifePath® Index 2055 Fund Class K Shares	Mutual Funds	5,840,933
	BlackRock LifePath® Index 2040 Fund Class K Shares	Mutual Funds	5,462,427
*	Fidelity Advisor Freedom® 2030 Fund Class Z6	Mutual Funds	2,986,805
*	Fidelity Advisor® Strategic Income Fund Class Z	Mutual Funds	2,272,409
*	Fidelity® International Index Fund	Mutual Funds	2,403,691
*	Fidelity® Mid Cap Index Fund	Mutual Funds	2,576,245
	LifePath Index 2060 Fund	Mutual Funds	4,426,489
*	Fidelity Advisor® Investment Grade Bond Fund Class Z	Mutual Funds	1,414,287
	American Century Mid Cap Value Fund R6 Class	Mutual Funds	1,885,539
*	Fidelity Advisor Freedom® 2055 Fund Class Z6	Mutual Funds	2,230,916
	JPMorgan Core Bond Fund Class R6	Mutual Funds	2,150,181
	JPMorgan Mid Cap Growth Fund Class R6	Mutual Funds	1,545,094
	AB Small Cap Growth Portfolio Class Z	Mutual Funds	1,959,591
	MFS New Discovery Value Fund Class R6	Mutual Funds	1,771,331
	MFS International Growth Fund Class R6	Mutual Funds	2,358,614
	BlackRock LifePath® Index 2035 Fund Class K Shares	Mutual Funds	3,002,868
*	Fidelity Advisor Freedom® 2025 Fund Class Z6	Mutual Funds	925,644
*	Fidelity® Small Cap Index Fund	Mutual Funds	1,520,898
	BlackRock LifePath® Index 2030 Fund Class K Shares	Mutual Funds	2,088,469
*	Fidelity ® Government Money Market Fund Class K6	Mutual Funds	1,326,614
*	Fidelity Advisor Freedom® 2020 Fund Class Z6	Mutual Funds	731,046
*	Fidelity Advisor Freedom® 2010 Fund Class Z6	Mutual Funds	449,344
*	Fidelity Advisor® International Small Cap Fund Class Z	Mutual Funds	446,633
*	Fidelity Advisor Freedom® 2060 Fund Class Z6	Mutual Funds	462,200
*	Fidelity Advisor Freedom® Income Fund Class Z6	Mutual Funds	187,195
*	Fidelity Advisor Freedom® 2015 Fund Class Z6	Mutual Funds	140,737
	BlackRock LifePath® Index Retirement Fund Class K Shares	Mutual Funds	1,268,533
	LifePath Index 2065 Fund	Mutual Funds	397,237
*	Fidelity Advisor Freedom® 2065 Fund Class Z6	Mutual Funds	127,056
*	JPMorgan Large Cap Growth Fund Class R6	Mutual Funds	9,403,594
*	Fidelity Advisor® Emerging Markets Fund Class Z	Mutual Funds	658,154
*	Fidelity Advisor® Capital & Income Fund Class Z	Mutual Funds	1,385,683

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan  
EIN: 13-6180380  
Plan # 001**

**Schedule of Assets (Held at End of Year) (Schedule H, Line 4i)  
December 31, 2024**

(a)	(b) Identity of issuer, borrower, lessor or similar party	(c) Description of Investment including Maturity Date, Rate of Interest, Collateral, Par or Maturity Value	(e) Current Value
	Guaranteed investment contract:		
*	Fidelity Advisor Stable Value Portfolio Class I	Guaranteed Investment contract	2,594,090
	Total investments, at fair value		123,569,558
*	Notes receivable from participants	Interest rates ranging from 4.25% to 9.50%, maturing at various dates, secured by participant account balance	98,628
	Total investments		<u>\$ 123,668,186</u>

\* Represents a party-in-interest as defined by ERISA.

Note: The cost of participant-directed investments is not required to be disclosed.

See Independent Auditor's Report.



**Independent Member of Nexia**

**[cohnreznick.com](http://cohnreznick.com)**

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

**Financial Statements  
(With Supplementary Information)  
and Independent Auditor's Report**

**December 31, 2024 and 2023**

---

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

Index

	<u>Page</u>
Independent Auditor's Report	2
Financial Statements	
Statements of Net Assets Available for Benefits	6
Statements of Changes in Net Assets Available for Benefits	7
Notes to Financial Statements	8
Supplementary Information	
Schedule of Delinquent Contributions (Schedule H, Line 4a)	16
Schedule of Assets (Held at End of Year) (Schedule H, Line 4i)	17

Independent Auditor's Report

To the Plan Administrator  
American Society of Clinical Oncology 401(k) Profit Sharing Plan

*Scope and Nature of the ERISA Section 103(a)(3)(C) Audit*

We have performed audits of the financial statements of American Society of Clinical Oncology 401(k) Profit Sharing Plan (the "Plan"), an employee benefit plan subject to the Employee Retirement Income Security Act of 1974 ("ERISA"), as permitted by ERISA Section 103(a)(3)(C). The financial statements comprise the statements of net assets available for benefits as of December 31, 2024 and 2023, and the related statements of changes in net assets available for benefits for the years then ended and the related notes to the financial statements.

Management, having determined it is permissible in the circumstances, has elected to have the audits of the Plan's financial statements performed in accordance with ERISA Section 103(a)(3)(C) pursuant to 29 CFR 2520.103-8 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA. As permitted by ERISA Section 103(a)(3)(C), our audit need not extend to any statements or information related to assets held for investment of the Plan ("investment information") by a bank or similar institution or insurance carrier that is regulated, supervised, and subject to periodic examination by a state or federal agency, provided that the statements or information regarding assets so held are prepared and certified to by the bank or similar institution or insurance carrier in accordance with 29 CFR 2520.103-5 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA ("qualified institution").

Management has obtained certifications from a qualified institution as of December 31, 2024 and 2023, and for the years ended December 31, 2024 and 2023, stating that the certified investment information, as described in Note 4 to the financial statements, is complete and accurate.

*Opinion*

In our opinion, based on our audits and on the procedures performed as described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section:

- The amounts and disclosures in the accompanying financial statements, other than those agreed to or derived from the certified investment information, are presented fairly, in all material respects, in accordance with accounting principles generally accepted in the United States of America.
- The information in the accompanying financial statements related to assets held by and certified to by a qualified institution agrees to, or is derived from, in all material respects, the information prepared and certified by an institution that management determined meets the requirements of ERISA Section 103(a)(3)(C).

### *Basis for Opinion*

We conducted our audits in accordance with auditing standards generally accepted in the United States of America ("GAAS"). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are required to be independent of the Plan and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our ERISA Section 103(a)(3)(C) audit opinion.

### *Responsibilities of Management for the Financial Statements*

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error. Management's election of the ERISA Section 103(a)(3)(C) audit does not affect management's responsibility for the financial statements.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Plan's ability to continue as a going concern for one year after the date that the financial statements are available to be issued.

Management is also responsible for maintaining a current Plan instrument, including all Plan amendments, administering the Plan, and determining that the Plan's transactions that are presented and disclosed in the financial statements are in conformity with the Plan's provisions, including maintaining sufficient records with respect to each of the participants, to determine the benefits due or which may become due to such participants.

### *Auditor's Responsibilities for the Audit of the Financial Statements*

Except as described in the *Scope and Nature of the ERISA Section 103(a)(3)(C) Audit* section of our report, our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a significant likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Plan's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Plan's ability to continue as a going concern for a reasonable period of time.

Our audits did not extend to the certified investment information, except for obtaining and reading the certification, comparing the certified investment information with the related information presented and disclosed in the financial statements, and reading the disclosures relating to the certified investment information to assess whether they are in accordance with the presentation and disclosure requirements of accounting principles generally accepted in the United States of America.

Accordingly, the objective of an ERISA Section 103(a)(3)(C) audit is not to express an opinion about whether the financial statements as a whole are presented fairly, in all material respects, in accordance with accounting principles generally accepted in the United States of America.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Other Matters

#### *Supplemental Schedules Required by ERISA*

The supplemental Schedule of Delinquent Contributions (Schedule H, Line 4a) for the year ended December 31, 2024, and the supplemental Schedule of Assets (Held at End of Year) (Schedule H, Line 4i) as of December 31, 2024, are presented for purposes of additional analysis and is not a required part of the financial statements but is supplementary information required by the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information included in the supplemental schedules, other than that agreed to or derived from the certified investment information, has been subjected to auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with GAAS. For information included in the supplemental schedules that agreed to or is derived from the certified investment information, we compared such information to the related certified investment information.

In forming our opinion on the supplemental schedules, we evaluated whether the supplemental schedules, other than the information agreed to or derived from the certified investment information, including their form and content, is presented in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA.

In our opinion:

- The form and content of the supplemental schedule, other than the information in the supplemental schedule that agreed to or is derived from the certified investment information, is presented, in all material respects, in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA.
- The information in the supplemental schedule related to assets held by and certified to by a qualified institution agrees to, or is derived from, in all material respects, the information prepared and certified by an institution that management determined meets the requirements of ERISA Section 103(a)(3)(C).

*CohnReznick LLP*

Bethesda, Maryland  
October 10, 2025

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

**Statements of Net Assets Available for Benefits  
December 31, 2024 and 2023**

	<u>2024</u>	<u>2023</u>
Assets		
Investments, at fair value	\$ 120,975,468	\$ 108,515,695
Investments, at contract value	<u>2,594,090</u>	<u>2,803,926</u>
Total investments	<u>123,569,558</u>	<u>111,319,621</u>
Receivables		
Notes receivable from participants	<u>98,628</u>	<u>258,133</u>
Total receivables	<u>98,628</u>	<u>258,133</u>
Net assets available for benefits	<u>\$ 123,668,186</u>	<u>\$ 111,577,754</u>

See Notes to Financial Statements.

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

**Statements of Changes in Net Assets Available for Benefits  
Years Ended December 31, 2024 and 2023**

	2024	2023
Additions		
Investment income		
Net appreciation in fair value of investments	\$ 12,085,130	\$ 14,764,618
Interest and dividend income	3,600,996	2,463,795
Total investment income	15,686,126	17,228,413
Interest income on notes receivable from participants	10,265	13,916
Contributions		
Participants	5,330,825	5,814,257
Employer	4,251,556	4,610,511
Rollovers	964,236	649,319
Total contributions	10,546,617	11,074,087
Total additions	26,243,008	28,316,416
Deductions		
Benefits paid to participants	14,063,982	8,817,031
Administrative expenses	88,594	122,239
Total deductions	14,152,576	8,939,270
Increase in net assets	12,090,432	19,377,146
Net assets available for benefits		
Beginning	111,577,754	92,200,608
End	\$ 123,668,186	\$ 111,577,754

See Notes to Financial Statements.

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

**Notes to Financial Statements  
December 31, 2024 and 2023**

**Note 1 - Description of Plan**

The following description of the American Society of Clinical Oncology 401(k) Profit Sharing Plan (the "Plan") provides only general information. Participants should refer to the Plan document and any amendments for more complete information.

**General**

The Plan is a defined contribution plan covering all eligible employees of the American Society of Clinical Oncology, Inc. (the "Society") and the ASCO Association (the "Association"), collectively, the "Organization". All employees are eligible to participate in the Plan upon hire and per the Plan are eligible to receive employer contributions at the start of the next calendar month of employment. However, for administrative purposes, employer contributions begin with the first paycheck. The 401(k) Plan Administrative Committee of the Society is responsible for the operation and administration of the Plan. Fidelity Management Trust Company ("Fidelity") serves as the trustee and record keeper of the Plan. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974 ("ERISA").

**Contributions**

The Plan provides for voluntary employee contributions between 1% and 90% of a participant's annual earnings up to the 401(k) contribution limit defined in the Internal Revenue Code (the "IRC"). Any contributions that exceed Internal Revenue Service (the "IRS") limitations are returned to the participant as a corrective distribution. Such amounts, if any, are netted against participant contributions in the financial statements. Participants may also contribute amounts representing distributions from other qualified defined benefit or defined contribution plans ("rollovers").

Participants direct the investment of their contributions into various investment options offered by the Plan. The Company makes safe harbor nonelective contributions equal to 3% of the employee's eligible wages. The Company also may make discretionary contributions of a fixed percentage of compensation for each participant. The discretionary contribution rate for each of the years ended December 31, 2024 and 2023 was 4.5%. During the years ended December 31, 2024 and 2023, the Company contributed nonelective contributions amounting to \$1,750,586 and \$1,885,877, respectively, and discretionary contributions amounting to \$2,500,970 and \$2,724,634, respectively.

**Participant accounts**

Each participant's account is credited with the participant's contributions, including amounts rolled over from other qualified plans, and allocation of (a) Organization's contributions, (b) Plan earnings (losses), and (c) administrative expenses (until March 23, 2022). Allocations are based on participant compensation or account balances or specific participant transactions, as defined. The benefit to which a participant is entitled is the benefit that can be provided from the participant's vested account.

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

**Notes to Financial Statements  
December 31, 2024 and 2023**

**Vesting**

Participants are immediately vested in all participant contributions and safe harbor nonelective employer contributions plus actual earnings thereon. Employees vest in the discretionary nonelective contributions in accordance with the following schedule:

<u>Years of Service</u>	<u>Vesting Percentage</u>
Less than 1 year	0%
1	25%
2	50%
3	75%
4	100%

**Forfeitures**

Forfeitures occur when an employee ends participation in the Plan prior to becoming fully vested in his/her discretionary portion of the account. These forfeited nonvested balances are used to reduce future employer contributions. Forfeitures of \$125,000 and \$104,197, respectively, were used to reduce employer contributions during the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024 and 2023, forfeited nonvested accounts totaled \$78,518 and \$25,849, respectively.

**Notes receivable from participants**

Participants may borrow from their investment accounts a hardship loan of a minimum of \$1,000 up to a maximum of \$50,000, or 50% of their vested account balance, whichever is less. Under the CARES Act, the maximum loan was increased to \$100,000 and the repayment period for loans was extended up to one year, if applicable. The notes are secured by the balance in the participant's account and bear interest at rates that range from 4.25% to 9.5%, which is commensurate with the average of the prime lending rates at the time the note is taken out by the participant. The notes are measured at their unpaid principal balance plus any accrued but unpaid interest. The notes are to be repaid by salary deductions over periods no longer than five years unless the proceeds are used to buy the participant's main residence. Under the Plan, if a participant ceases to make loan repayments and the Plan administrator deems the participant loan to be in default, the participant loan balance is reduced and a benefit payment is recorded.

**Payment of benefits**

Upon termination of service due to death, disability, retirement or any other reason, a participant or beneficiary may elect to receive either a lump sum amount equal to the value of the participant's vested interest in his or her account. Accounts with balances of \$5,000 or less are automatically distributed and rolled over into an individual retirement account established at Fidelity Management Trust Company. Lump sum distributions may be in the form of (i) paid directly to participant or beneficiary; (ii) direct rollover to qualified eligible plan or individual retirement account; and/or (iii) combination of direct payment or rollover. The participant may also receive partial withdrawal after termination of employment. The Plan also allows for hardship withdrawals in accordance with the terms of the Plan document.

**Administrative expenses**

Participant transaction charges incurred by participants are charged directly to their accounts. Plan administrative expenses are paid by the Society.

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

**Notes to Financial Statements  
December 31, 2024 and 2023**

**Income tax status**

The Plan operates under an adopted prototype non-standardized pre-approved profit sharing plan with a cash or deferral arrangement of FMR LLC (the "prototype plan") that most recently received a favorable opinion letter from the IRS on June 30, 2020, which stated that the prototype plan and related trust are designed in accordance with applicable sections of the IRC. While the Plan has been amended since adopting the prototype plan, the Society believes the Plan is currently being operated in accordance with the IRC.

Accounting principles generally accepted in the United States of America require Plan management to evaluate tax positions taken by the Plan and recognize a tax liability if the Plan has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress.

**Note 2 - Summary of accounting policies**

**Basis of accounting**

The Plan's financial statements are prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP").

**Use of estimates**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Plan's management to make estimates and assumptions that affect the reported amounts of assets and liabilities and changes therein, and disclosure of contingent assets and liabilities. Actual results could differ from those estimates.

**Investment valuation and income recognition**

Investments are reported at fair value. Shares of registered investment companies are valued at quoted market prices in an active market, which represent the net asset value of shares held by the Plan at year end. The Plan's direct investment in the fully benefit-responsive investment contract is reported at contract value.

The preceding methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date. Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded as earned. Dividends are recorded on the ex-dividend date. The Plan presents in the statements of changes in net assets available for benefits the net appreciation or (depreciation) in the fair value of its investments, which consists of the realized gains or losses and the unrealized appreciation or (depreciation) of those investments.

**Contributions**

Contributions from Plan participants and contributions from the Organization are recorded in the year in which the employee contributions are withheld from compensation.

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

**Notes to Financial Statements  
December 31, 2024 and 2023**

**Notes receivable from participants**

Notes receivable from participants are measured at the unpaid principal balances plus any accrued but unpaid interest. Interest income is recorded on the accrual basis. Related fees are recorded as administrative expenses and are expensed when they are incurred.

**Payment of benefits**

Benefits are recorded when paid.

**Reclassifications**

Certain items from the prior year financial statements have been reclassified to conform to the current year presentation.

**Note 3 - Plan termination**

Although it has not expressed any intent to do so, the Organization has the right to discontinue its contributions, amend, or terminate the Plan subject to the provisions of ERISA at any time without the consent of participants. If the Plan is terminated, the value of all employer contributions becomes immediately fully vested.

**Note 4 - Certified investments**

The Plan administrator has elected the method of compliance permitted by 29 CFR 2520.103-8 of the DOL's Rules and Regulations for Reporting and Disclosure under ERISA. Investments and notes receivable from participants held at December 31, 2024 and 2023, and investment income and interest income on notes receivable from participants for the years then ended, that is disclosed in the accompanying financial statements and supplemental schedule of assets (held at end of year) as of December 31, 2024 was obtained or derived from information supplied to the Plan administrator and certified as complete and accurate by Fidelity Management Trust Company, the trustee of the Plan.

**Note 5 - Fair value measurements**

The framework for measuring fair value provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities ("Level 1") and the lowest priority to unobservable inputs ("Level 3").

The three levels of the fair value hierarchy under U.S. GAAP are described as follows:

Level 1 - Observable inputs that reflect quoted prices for identical assets or liabilities in active markets, such as stock quotes.

Level 2 - Includes inputs other than Level 1 that are directly or indirectly observable in the marketplace, such as yield curves or other market data.

Level 3 - Unobservable inputs which reflect the reporting entity's assessment of the assumptions that market participants would use in pricing the asset or liability including assumptions about risk, such as bid/ask spreads and liquidity discounts.

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

**Notes to Financial Statements  
December 31, 2024 and 2023**

Following is a description of the valuation methodology used for assets measured at fair value. There have been no changes in the valuation methodology used at December 31, 2024 and 2023. This method may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Plan believes its valuation method is appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

*Mutual funds* - Valued at the daily closing price as reported by the fund. Mutual funds held by the Plan are open-end mutual funds that are registered with the Securities and Exchange Commission. These funds are required to publish their daily net asset value and to transact at that price. The mutual funds held by the Plan are deemed to be actively traded.

Investments, recorded at fair value and measured on a recurring basis, consist of the following at:

Assets at Fair Value as of December 31, 2024				
	Total	Level 1	Level 2	Level 3
Mutual funds	\$ 120,975,468	\$ 120,975,468	\$ -	\$ -
Assets at Fair Value as of December 31, 2023				
	Total	Level 1	Level 2	Level 3
Mutual funds	\$ 108,515,695	\$ 108,515,695	\$ -	\$ -

**Note 6 - Guaranteed Investment Contract with Fidelity Management Trust Company**

The Plan maintains a benefit-responsive investment contract with Fidelity titled the "Fidelity Advisor Stable Value Portfolio Class I" (the "Trust") amounting to \$2,594,090 and \$2,803,926 as of December 31, 2024 and 2023, respectively. The Trust invests primarily in synthetic investment contracts backed by high credit-quality fixed income investments and traditional investments issued by insurance companies and banks. The account is credited with earnings on the underlying investments, and charged for plan withdrawals and administrative expenses. Because the guaranteed investment contract is fully benefit-responsive, contract value is the relevant measurement attribute for that portion of the net assets available for benefits attributable to the guaranteed investment contract.

Contract value represents contributions made under the contract, plus earnings, less participant withdrawals and administrative expenses. Participants may ordinarily direct withdrawals or transfer all or a portion of their investment at contract value.

Certain events could limit the Plan's ability to transact at contract value with Plan participants. Such events include: (a) amendments to the Plan document (including complete or partial Plan termination or merger with another plan), (b) the operation of another investment option that is deemed to be competitive with the Trust, or (c) another pension plan is established in which Plan participants are eligible to contribute by payroll deductions. The Plan administrator does not believe that the occurrence of any of these events is probable.

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

**Notes to Financial Statements  
December 31, 2024 and 2023**

**Note 7 - Related party and party-in-interest transactions**

The guaranteed investment contract and many of the mutual funds offered as Plan investments are managed by Fidelity. Fidelity is the trustee as defined by the Plan and, therefore, these transactions qualify as party-in-interest transactions. As described in Note 1, the Plan received amounts from the excess of recordkeeping over plan expenses.

**Note 8 - Reconciliation of financial statements to Form 5500**

The following is a reconciliation of net assets available for benefits and additions per the financial statements to Form 5500 as of December 31, 2024 and 2023:

	2024	2023
Net assets available for plan benefits, financial statements	\$ 123,668,186	\$ 111,577,754
Adjustment from contract value to fair value for fully benefit-responsive investment contracts	(172,561)	(164,123)
Net assets available for plan benefits, Form 5500	\$ 123,495,625	\$ 111,413,631
	2024	2023
Total increase per the financial statements	\$ 12,090,432	\$ 19,377,146
2024 adjustment from contract value to fair value for fully benefit-responsive investments	(172,561)	-
2023 adjustment from contract value to fair value for fully benefit-responsive investments	164,123	(164,123)
2022 adjustment from contract value to fair value for fully benefit-responsive investments	-	222,560
Net income per Form 5500	\$ 12,081,994	\$ 19,435,583

**Note 9 - Risks and uncertainties**

The Plan invests in various investment securities. Investment securities are exposed to various risks, including interest rate, market and credit risks. Due to the level of risk associated with certain investment securities, it is possible that changes in the fair values of investment securities will occur in the near-term, and that such changes could materially affect participants' account balances and the amounts reported in the statements of net assets available for benefits.

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

**Notes to Financial Statements  
December 31, 2024 and 2023**

**Note 10 - Subsequent events**

Events that occur after the statement of net assets available for benefits date but before the financial statements were available to be issued must be evaluated for recognition or disclosure. The effects of subsequent events that provide evidence about conditions that existed at the statement of net assets available for benefits date are recognized in the accompanying financial statements. Subsequent events which provide evidence about conditions that existed after the statements of net assets available for benefits date require disclosure in the accompanying notes. Management evaluated the activity of the Plan through October 10, 2025 (the date the financial statements were available to be issued) and concluded that no subsequent events have occurred that would require recognition in the financial statements or disclosure is required in the notes to the financial statements.

**Note 11 - Nonexempt transactions**

As reported on the supplemental Schedule of Delinquent Contributions (Schedule H, Line 4a), \$1,235 of Plan participant contributions were not remitted to the trust within the time frame specified by the DOL's regulations 29 (CFR 2510.3-102), thus constituting nonexempt transactions between the Plan and the Organization relating to the 2015 Plan year that was discovered by Plan management during the 2024 Plan year. The late participant contribution of \$1,235 was paid into the plan on September 23, 2025. As of the date these Plan financial statements were available to be issued, Plan management was in the process of preparing an application to submit to the DOL's Voluntary Fiduciary Correction Program to complete the correction process.

## **Supplementary Information**

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan  
EIN: 13-6180380  
Plan # 001**

**Schedule of Delinquent Participant Contributions (Schedule H, Line 4a)  
Year end of December 31, 2024**

Year	Participant contributions transferred late to plan	Check here if participant loan repayments are included	Total that constitute nonexempt prohibited transactions			Total fully corrected under VFCP and Prohibited Transaction Exemption 2002-51
			Contributions not corrected	Contributions corrected outside the Voluntary Fiduciary Correction Program ("VFCP")	Contributions pending correction in VFCP	
2015	\$ 1,235		\$ 1,235	\$ -	\$ -	\$ -

See Independent Auditor's Report.

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan  
EIN: 13-6180380  
Plan # 001**

**Schedule of Assets (Held at End of Year) (Schedule H, Line 4i)  
December 31, 2024**

(a)	(b) Identity of issuer, borrower, lessor or similar party	(c) Description of Investment including Maturity Date, Rate of Interest, Collateral, Par or Maturity Value	(e) Current Value
Mutual funds:			
*	Fidelity® 500 Index Fund	Mutual Funds	\$ 15,263,154
*	Fidelity Advisor Freedom® 2040 Fund Class Z6	Mutual Funds	5,771,686
	BlackRock Equity Dividend Fund K Shares	Mutual Funds	4,764,533
*	Fidelity Advisor Freedom® 2050 Fund Class Z6	Mutual Funds	4,560,101
*	Fidelity Advisor Freedom® 2035 Fund Class Z6	Mutual Funds	6,535,708
	BlackRock LifePath® Index 2045 Fund Class K Shares	Mutual Funds	6,468,155
*	Fidelity Advisor Freedom® 2045 Fund Class Z6	Mutual Funds	4,948,140
	BlackRock LifePath® Index 2050 Fund Class K Shares	Mutual Funds	6,857,534
	BlackRock LifePath® Index 2055 Fund Class K Shares	Mutual Funds	5,840,933
	BlackRock LifePath® Index 2040 Fund Class K Shares	Mutual Funds	5,462,427
*	Fidelity Advisor Freedom® 2030 Fund Class Z6	Mutual Funds	2,986,805
*	Fidelity Advisor® Strategic Income Fund Class Z	Mutual Funds	2,272,409
*	Fidelity® International Index Fund	Mutual Funds	2,403,691
*	Fidelity® Mid Cap Index Fund	Mutual Funds	2,576,245
	LifePath Index 2060 Fund	Mutual Funds	4,426,489
*	Fidelity Advisor® Investment Grade Bond Fund Class Z	Mutual Funds	1,414,287
	American Century Mid Cap Value Fund R6 Class	Mutual Funds	1,885,539
*	Fidelity Advisor Freedom® 2055 Fund Class Z6	Mutual Funds	2,230,916
	JPMorgan Core Bond Fund Class R6	Mutual Funds	2,150,181
	JPMorgan Mid Cap Growth Fund Class R6	Mutual Funds	1,545,094
	AB Small Cap Growth Portfolio Class Z	Mutual Funds	1,959,591
	MFS New Discovery Value Fund Class R6	Mutual Funds	1,771,331
	MFS International Growth Fund Class R6	Mutual Funds	2,358,614
	BlackRock LifePath® Index 2035 Fund Class K Shares	Mutual Funds	3,002,868
*	Fidelity Advisor Freedom® 2025 Fund Class Z6	Mutual Funds	925,644
*	Fidelity® Small Cap Index Fund	Mutual Funds	1,520,898
	BlackRock LifePath® Index 2030 Fund Class K Shares	Mutual Funds	2,088,469
*	Fidelity ® Government Money Market Fund Class K6	Mutual Funds	1,326,614
*	Fidelity Advisor Freedom® 2020 Fund Class Z6	Mutual Funds	731,046
*	Fidelity Advisor Freedom® 2010 Fund Class Z6	Mutual Funds	449,344
*	Fidelity Advisor® International Small Cap Fund Class Z	Mutual Funds	446,633
*	Fidelity Advisor Freedom® 2060 Fund Class Z6	Mutual Funds	462,200
*	Fidelity Advisor Freedom® Income Fund Class Z6	Mutual Funds	187,195
*	Fidelity Advisor Freedom® 2015 Fund Class Z6	Mutual Funds	140,737
	BlackRock LifePath® Index Retirement Fund Class K Shares	Mutual Funds	1,268,533
	LifePath Index 2065 Fund	Mutual Funds	397,237
*	Fidelity Advisor Freedom® 2065 Fund Class Z6	Mutual Funds	127,056
*	JPMorgan Large Cap Growth Fund Class R6	Mutual Funds	9,403,594
*	Fidelity Advisor® Emerging Markets Fund Class Z	Mutual Funds	658,154
*	Fidelity Advisor® Capital & Income Fund Class Z	Mutual Funds	1,385,683

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan  
EIN: 13-6180380  
Plan # 001**

**Schedule of Assets (Held at End of Year) (Schedule H, Line 4i)  
December 31, 2024**

(a)	(b) Identity of issuer, borrower, lessor or similar party	(c) Description of Investment including Maturity Date, Rate of Interest, Collateral, Par or Maturity Value	(e) Current Value
	Guaranteed investment contract:		
*	Fidelity Advisor Stable Value Portfolio Class I	Guaranteed Investment contract	2,594,090
	Total investments, at fair value		123,569,558
*	Notes receivable from participants	Interest rates ranging from 4.25% to 9.50%, maturing at various dates, secured by participant account balance	98,628
	Total investments		<u>\$ 123,668,186</u>

\* Represents a party-in-interest as defined by ERISA.

Note: The cost of participant-directed investments is not required to be disclosed.

See Independent Auditor's Report.



**Independent Member of Nexia**

**[cohnreznick.com](http://cohnreznick.com)**

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

**Financial Statements  
(With Supplementary Information)  
and Independent Auditor's Report**

**December 31, 2024 and 2023**

---

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

Index

	<u>Page</u>
Independent Auditor's Report	2
Financial Statements	
Statements of Net Assets Available for Benefits	6
Statements of Changes in Net Assets Available for Benefits	7
Notes to Financial Statements	8
Supplementary Information	
Schedule of Delinquent Contributions (Schedule H, Line 4a)	16
Schedule of Assets (Held at End of Year) (Schedule H, Line 4i)	17

Independent Auditor's Report

To the Plan Administrator  
American Society of Clinical Oncology 401(k) Profit Sharing Plan

*Scope and Nature of the ERISA Section 103(a)(3)(C) Audit*

We have performed audits of the financial statements of American Society of Clinical Oncology 401(k) Profit Sharing Plan (the "Plan"), an employee benefit plan subject to the Employee Retirement Income Security Act of 1974 ("ERISA"), as permitted by ERISA Section 103(a)(3)(C). The financial statements comprise the statements of net assets available for benefits as of December 31, 2024 and 2023, and the related statements of changes in net assets available for benefits for the years then ended and the related notes to the financial statements.

Management, having determined it is permissible in the circumstances, has elected to have the audits of the Plan's financial statements performed in accordance with ERISA Section 103(a)(3)(C) pursuant to 29 CFR 2520.103-8 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA. As permitted by ERISA Section 103(a)(3)(C), our audit need not extend to any statements or information related to assets held for investment of the Plan ("investment information") by a bank or similar institution or insurance carrier that is regulated, supervised, and subject to periodic examination by a state or federal agency, provided that the statements or information regarding assets so held are prepared and certified to by the bank or similar institution or insurance carrier in accordance with 29 CFR 2520.103-5 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA ("qualified institution").

Management has obtained certifications from a qualified institution as of December 31, 2024 and 2023, and for the years ended December 31, 2024 and 2023, stating that the certified investment information, as described in Note 4 to the financial statements, is complete and accurate.

*Opinion*

In our opinion, based on our audits and on the procedures performed as described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section:

- The amounts and disclosures in the accompanying financial statements, other than those agreed to or derived from the certified investment information, are presented fairly, in all material respects, in accordance with accounting principles generally accepted in the United States of America.
- The information in the accompanying financial statements related to assets held by and certified to by a qualified institution agrees to, or is derived from, in all material respects, the information prepared and certified by an institution that management determined meets the requirements of ERISA Section 103(a)(3)(C).

### *Basis for Opinion*

We conducted our audits in accordance with auditing standards generally accepted in the United States of America ("GAAS"). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are required to be independent of the Plan and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our ERISA Section 103(a)(3)(C) audit opinion.

### *Responsibilities of Management for the Financial Statements*

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error. Management's election of the ERISA Section 103(a)(3)(C) audit does not affect management's responsibility for the financial statements.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Plan's ability to continue as a going concern for one year after the date that the financial statements are available to be issued.

Management is also responsible for maintaining a current Plan instrument, including all Plan amendments, administering the Plan, and determining that the Plan's transactions that are presented and disclosed in the financial statements are in conformity with the Plan's provisions, including maintaining sufficient records with respect to each of the participants, to determine the benefits due or which may become due to such participants.

### *Auditor's Responsibilities for the Audit of the Financial Statements*

Except as described in the *Scope and Nature of the ERISA Section 103(a)(3)(C) Audit* section of our report, our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a significant likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Plan's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Plan's ability to continue as a going concern for a reasonable period of time.

Our audits did not extend to the certified investment information, except for obtaining and reading the certification, comparing the certified investment information with the related information presented and disclosed in the financial statements, and reading the disclosures relating to the certified investment information to assess whether they are in accordance with the presentation and disclosure requirements of accounting principles generally accepted in the United States of America.

Accordingly, the objective of an ERISA Section 103(a)(3)(C) audit is not to express an opinion about whether the financial statements as a whole are presented fairly, in all material respects, in accordance with accounting principles generally accepted in the United States of America.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Other Matters

*Supplemental Schedules Required by ERISA*

The supplemental Schedule of Delinquent Contributions (Schedule H, Line 4a) for the year ended December 31, 2024, and the supplemental Schedule of Assets (Held at End of Year) (Schedule H, Line 4i) as of December 31, 2024, are presented for purposes of additional analysis and is not a required part of the financial statements but is supplementary information required by the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information included in the supplemental schedules, other than that agreed to or derived from the certified investment information, has been subjected to auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with GAAS. For information included in the supplemental schedules that agreed to or is derived from the certified investment information, we compared such information to the related certified investment information.

In forming our opinion on the supplemental schedules, we evaluated whether the supplemental schedules, other than the information agreed to or derived from the certified investment information, including their form and content, is presented in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA.

In our opinion:

- The form and content of the supplemental schedule, other than the information in the supplemental schedule that agreed to or is derived from the certified investment information, is presented, in all material respects, in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA.
- The information in the supplemental schedule related to assets held by and certified to by a qualified institution agrees to, or is derived from, in all material respects, the information prepared and certified by an institution that management determined meets the requirements of ERISA Section 103(a)(3)(C).

*CohnReznick LLP*

Bethesda, Maryland  
October 10, 2025

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

**Statements of Net Assets Available for Benefits  
December 31, 2024 and 2023**

	<u>2024</u>	<u>2023</u>
Assets		
Investments, at fair value	\$ 120,975,468	\$ 108,515,695
Investments, at contract value	<u>2,594,090</u>	<u>2,803,926</u>
Total investments	<u>123,569,558</u>	<u>111,319,621</u>
Receivables		
Notes receivable from participants	<u>98,628</u>	<u>258,133</u>
Total receivables	<u>98,628</u>	<u>258,133</u>
Net assets available for benefits	<u><u>\$ 123,668,186</u></u>	<u><u>\$ 111,577,754</u></u>

See Notes to Financial Statements.

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

**Statements of Changes in Net Assets Available for Benefits  
Years Ended December 31, 2024 and 2023**

	2024	2023
Additions		
Investment income		
Net appreciation in fair value of investments	\$ 12,085,130	\$ 14,764,618
Interest and dividend income	3,600,996	2,463,795
	15,686,126	17,228,413
Total investment income		
Interest income on notes receivable from participants	10,265	13,916
Contributions		
Participants	5,330,825	5,814,257
Employer	4,251,556	4,610,511
Rollovers	964,236	649,319
	10,546,617	11,074,087
Total contributions		
Total additions	26,243,008	28,316,416
Deductions		
Benefits paid to participants	14,063,982	8,817,031
Administrative expenses	88,594	122,239
	14,152,576	8,939,270
Total deductions		
Increase in net assets	12,090,432	19,377,146
Net assets available for benefits		
Beginning	111,577,754	92,200,608
End	\$ 123,668,186	\$ 111,577,754

See Notes to Financial Statements.

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

**Notes to Financial Statements  
December 31, 2024 and 2023**

**Note 1 - Description of Plan**

The following description of the American Society of Clinical Oncology 401(k) Profit Sharing Plan (the "Plan") provides only general information. Participants should refer to the Plan document and any amendments for more complete information.

**General**

The Plan is a defined contribution plan covering all eligible employees of the American Society of Clinical Oncology, Inc. (the "Society") and the ASCO Association (the "Association"), collectively, the "Organization". All employees are eligible to participate in the Plan upon hire and per the Plan are eligible to receive employer contributions at the start of the next calendar month of employment. However, for administrative purposes, employer contributions begin with the first paycheck. The 401(k) Plan Administrative Committee of the Society is responsible for the operation and administration of the Plan. Fidelity Management Trust Company ("Fidelity") serves as the trustee and record keeper of the Plan. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974 ("ERISA").

**Contributions**

The Plan provides for voluntary employee contributions between 1% and 90% of a participant's annual earnings up to the 401(k) contribution limit defined in the Internal Revenue Code (the "IRC"). Any contributions that exceed Internal Revenue Service (the "IRS") limitations are returned to the participant as a corrective distribution. Such amounts, if any, are netted against participant contributions in the financial statements. Participants may also contribute amounts representing distributions from other qualified defined benefit or defined contribution plans ("rollovers").

Participants direct the investment of their contributions into various investment options offered by the Plan. The Company makes safe harbor nonelective contributions equal to 3% of the employee's eligible wages. The Company also may make discretionary contributions of a fixed percentage of compensation for each participant. The discretionary contribution rate for each of the years ended December 31, 2024 and 2023 was 4.5%. During the years ended December 31, 2024 and 2023, the Company contributed nonelective contributions amounting to \$1,750,586 and \$1,885,877, respectively, and discretionary contributions amounting to \$2,500,970 and \$2,724,634, respectively.

**Participant accounts**

Each participant's account is credited with the participant's contributions, including amounts rolled over from other qualified plans, and allocation of (a) Organization's contributions, (b) Plan earnings (losses), and (c) administrative expenses (until March 23, 2022). Allocations are based on participant compensation or account balances or specific participant transactions, as defined. The benefit to which a participant is entitled is the benefit that can be provided from the participant's vested account.

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

**Notes to Financial Statements  
December 31, 2024 and 2023**

**Vesting**

Participants are immediately vested in all participant contributions and safe harbor nonelective employer contributions plus actual earnings thereon. Employees vest in the discretionary nonelective contributions in accordance with the following schedule:

<u>Years of Service</u>	<u>Vesting Percentage</u>
Less than 1 year	0%
1	25%
2	50%
3	75%
4	100%

**Forfeitures**

Forfeitures occur when an employee ends participation in the Plan prior to becoming fully vested in his/her discretionary portion of the account. These forfeited nonvested balances are used to reduce future employer contributions. Forfeitures of \$125,000 and \$104,197, respectively, were used to reduce employer contributions during the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024 and 2023, forfeited nonvested accounts totaled \$78,518 and \$25,849, respectively.

**Notes receivable from participants**

Participants may borrow from their investment accounts a hardship loan of a minimum of \$1,000 up to a maximum of \$50,000, or 50% of their vested account balance, whichever is less. Under the CARES Act, the maximum loan was increased to \$100,000 and the repayment period for loans was extended up to one year, if applicable. The notes are secured by the balance in the participant's account and bear interest at rates that range from 4.25% to 9.5%, which is commensurate with the average of the prime lending rates at the time the note is taken out by the participant. The notes are measured at their unpaid principal balance plus any accrued but unpaid interest. The notes are to be repaid by salary deductions over periods no longer than five years unless the proceeds are used to buy the participant's main residence. Under the Plan, if a participant ceases to make loan repayments and the Plan administrator deems the participant loan to be in default, the participant loan balance is reduced and a benefit payment is recorded.

**Payment of benefits**

Upon termination of service due to death, disability, retirement or any other reason, a participant or beneficiary may elect to receive either a lump sum amount equal to the value of the participant's vested interest in his or her account. Accounts with balances of \$5,000 or less are automatically distributed and rolled over into an individual retirement account established at Fidelity Management Trust Company. Lump sum distributions may be in the form of (i) paid directly to participant or beneficiary; (ii) direct rollover to qualified eligible plan or individual retirement account; and/or (iii) combination of direct payment or rollover. The participant may also receive partial withdrawal after termination of employment. The Plan also allows for hardship withdrawals in accordance with the terms of the Plan document.

**Administrative expenses**

Participant transaction charges incurred by participants are charged directly to their accounts. Plan administrative expenses are paid by the Society.

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

**Notes to Financial Statements  
December 31, 2024 and 2023**

**Income tax status**

The Plan operates under an adopted prototype non-standardized pre-approved profit sharing plan with a cash or deferral arrangement of FMR LLC (the "prototype plan") that most recently received a favorable opinion letter from the IRS on June 30, 2020, which stated that the prototype plan and related trust are designed in accordance with applicable sections of the IRC. While the Plan has been amended since adopting the prototype plan, the Society believes the Plan is currently being operated in accordance with the IRC.

Accounting principles generally accepted in the United States of America require Plan management to evaluate tax positions taken by the Plan and recognize a tax liability if the Plan has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress.

**Note 2 - Summary of accounting policies**

**Basis of accounting**

The Plan's financial statements are prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP").

**Use of estimates**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Plan's management to make estimates and assumptions that affect the reported amounts of assets and liabilities and changes therein, and disclosure of contingent assets and liabilities. Actual results could differ from those estimates.

**Investment valuation and income recognition**

Investments are reported at fair value. Shares of registered investment companies are valued at quoted market prices in an active market, which represent the net asset value of shares held by the Plan at year end. The Plan's direct investment in the fully benefit-responsive investment contract is reported at contract value.

The preceding methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date. Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded as earned. Dividends are recorded on the ex-dividend date. The Plan presents in the statements of changes in net assets available for benefits the net appreciation or (depreciation) in the fair value of its investments, which consists of the realized gains or losses and the unrealized appreciation or (depreciation) of those investments.

**Contributions**

Contributions from Plan participants and contributions from the Organization are recorded in the year in which the employee contributions are withheld from compensation.

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

**Notes to Financial Statements  
December 31, 2024 and 2023**

**Notes receivable from participants**

Notes receivable from participants are measured at the unpaid principal balances plus any accrued but unpaid interest. Interest income is recorded on the accrual basis. Related fees are recorded as administrative expenses and are expensed when they are incurred.

**Payment of benefits**

Benefits are recorded when paid.

**Reclassifications**

Certain items from the prior year financial statements have been reclassified to conform to the current year presentation.

**Note 3 - Plan termination**

Although it has not expressed any intent to do so, the Organization has the right to discontinue its contributions, amend, or terminate the Plan subject to the provisions of ERISA at any time without the consent of participants. If the Plan is terminated, the value of all employer contributions becomes immediately fully vested.

**Note 4 - Certified investments**

The Plan administrator has elected the method of compliance permitted by 29 CFR 2520.103-8 of the DOL's Rules and Regulations for Reporting and Disclosure under ERISA. Investments and notes receivable from participants held at December 31, 2024 and 2023, and investment income and interest income on notes receivable from participants for the years then ended, that is disclosed in the accompanying financial statements and supplemental schedule of assets (held at end of year) as of December 31, 2024 was obtained or derived from information supplied to the Plan administrator and certified as complete and accurate by Fidelity Management Trust Company, the trustee of the Plan.

**Note 5 - Fair value measurements**

The framework for measuring fair value provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities ("Level 1") and the lowest priority to unobservable inputs ("Level 3").

The three levels of the fair value hierarchy under U.S. GAAP are described as follows:

Level 1 - Observable inputs that reflect quoted prices for identical assets or liabilities in active markets, such as stock quotes.

Level 2 - Includes inputs other than Level 1 that are directly or indirectly observable in the marketplace, such as yield curves or other market data.

Level 3 - Unobservable inputs which reflect the reporting entity's assessment of the assumptions that market participants would use in pricing the asset or liability including assumptions about risk, such as bid/ask spreads and liquidity discounts.

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

**Notes to Financial Statements  
December 31, 2024 and 2023**

Following is a description of the valuation methodology used for assets measured at fair value. There have been no changes in the valuation methodology used at December 31, 2024 and 2023. This method may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Plan believes its valuation method is appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

*Mutual funds* - Valued at the daily closing price as reported by the fund. Mutual funds held by the Plan are open-end mutual funds that are registered with the Securities and Exchange Commission. These funds are required to publish their daily net asset value and to transact at that price. The mutual funds held by the Plan are deemed to be actively traded.

Investments, recorded at fair value and measured on a recurring basis, consist of the following at:

Assets at Fair Value as of December 31, 2024				
	Total	Level 1	Level 2	Level 3
Mutual funds	\$ 120,975,468	\$ 120,975,468	\$ -	\$ -
Assets at Fair Value as of December 31, 2023				
	Total	Level 1	Level 2	Level 3
Mutual funds	\$ 108,515,695	\$ 108,515,695	\$ -	\$ -

**Note 6 - Guaranteed Investment Contract with Fidelity Management Trust Company**

The Plan maintains a benefit-responsive investment contract with Fidelity titled the "Fidelity Advisor Stable Value Portfolio Class I" (the "Trust") amounting to \$2,594,090 and \$2,803,926 as of December 31, 2024 and 2023, respectively. The Trust invests primarily in synthetic investment contracts backed by high credit-quality fixed income investments and traditional investments issued by insurance companies and banks. The account is credited with earnings on the underlying investments, and charged for plan withdrawals and administrative expenses. Because the guaranteed investment contract is fully benefit-responsive, contract value is the relevant measurement attribute for that portion of the net assets available for benefits attributable to the guaranteed investment contract.

Contract value represents contributions made under the contract, plus earnings, less participant withdrawals and administrative expenses. Participants may ordinarily direct withdrawals or transfer all or a portion of their investment at contract value.

Certain events could limit the Plan's ability to transact at contract value with Plan participants. Such events include: (a) amendments to the Plan document (including complete or partial Plan termination or merger with another plan), (b) the operation of another investment option that is deemed to be competitive with the Trust, or (c) another pension plan is established in which Plan participants are eligible to contribute by payroll deductions. The Plan administrator does not believe that the occurrence of any of these events is probable.

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

**Notes to Financial Statements  
December 31, 2024 and 2023**

**Note 7 - Related party and party-in-interest transactions**

The guaranteed investment contract and many of the mutual funds offered as Plan investments are managed by Fidelity. Fidelity is the trustee as defined by the Plan and, therefore, these transactions qualify as party-in-interest transactions. As described in Note 1, the Plan received amounts from the excess of recordkeeping over plan expenses.

**Note 8 - Reconciliation of financial statements to Form 5500**

The following is a reconciliation of net assets available for benefits and additions per the financial statements to Form 5500 as of December 31, 2024 and 2023:

	2024	2023
Net assets available for plan benefits, financial statements	\$ 123,668,186	\$ 111,577,754
Adjustment from contract value to fair value for fully benefit-responsive investment contracts	(172,561)	(164,123)
Net assets available for plan benefits, Form 5500	\$ 123,495,625	\$ 111,413,631
	2024	2023
Total increase per the financial statements	\$ 12,090,432	\$ 19,377,146
2024 adjustment from contract value to fair value for fully benefit-responsive investments	(172,561)	-
2023 adjustment from contract value to fair value for fully benefit-responsive investments	164,123	(164,123)
2022 adjustment from contract value to fair value for fully benefit-responsive investments	-	222,560
Net income per Form 5500	\$ 12,081,994	\$ 19,435,583

**Note 9 - Risks and uncertainties**

The Plan invests in various investment securities. Investment securities are exposed to various risks, including interest rate, market and credit risks. Due to the level of risk associated with certain investment securities, it is possible that changes in the fair values of investment securities will occur in the near-term, and that such changes could materially affect participants' account balances and the amounts reported in the statements of net assets available for benefits.

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan**

**Notes to Financial Statements  
December 31, 2024 and 2023**

**Note 10 - Subsequent events**

Events that occur after the statement of net assets available for benefits date but before the financial statements were available to be issued must be evaluated for recognition or disclosure. The effects of subsequent events that provide evidence about conditions that existed at the statement of net assets available for benefits date are recognized in the accompanying financial statements. Subsequent events which provide evidence about conditions that existed after the statements of net assets available for benefits date require disclosure in the accompanying notes. Management evaluated the activity of the Plan through October 10, 2025 (the date the financial statements were available to be issued) and concluded that no subsequent events have occurred that would require recognition in the financial statements or disclosure is required in the notes to the financial statements.

**Note 11 - Nonexempt transactions**

As reported on the supplemental Schedule of Delinquent Contributions (Schedule H, Line 4a), \$1,235 of Plan participant contributions were not remitted to the trust within the time frame specified by the DOL's regulations 29 (CFR 2510.3-102), thus constituting nonexempt transactions between the Plan and the Organization relating to the 2015 Plan year that was discovered by Plan management during the 2024 Plan year. The late participant contribution of \$1,235 was paid into the plan on September 23, 2025. As of the date these Plan financial statements were available to be issued, Plan management was in the process of preparing an application to submit to the DOL's Voluntary Fiduciary Correction Program to complete the correction process.

## **Supplementary Information**

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan  
EIN: 13-6180380  
Plan # 001**

**Schedule of Delinquent Participant Contributions (Schedule H, Line 4a)  
Year end of December 31, 2024**

Year	Participant contributions transferred late to plan	Check here if participant loan repayments are included	Total that constitute nonexempt prohibited transactions			Total fully corrected under VFCP and Prohibited Transaction Exemption 2002-51
			Contributions not corrected	Contributions corrected outside the Voluntary Fiduciary Correction Program ("VFCP")	Contributions pending correction in VFCP	
2015	\$ 1,235		\$ 1,235	\$ -	\$ -	\$ -

See Independent Auditor's Report.

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan  
EIN: 13-6180380  
Plan # 001**

**Schedule of Assets (Held at End of Year) (Schedule H, Line 4i)  
December 31, 2024**

(a)	(b) Identity of issuer, borrower, lessor or similar party	(c) Description of Investment including Maturity Date, Rate of Interest, Collateral, Par or Maturity Value	(e) Current Value
Mutual funds:			
*	Fidelity® 500 Index Fund	Mutual Funds	\$ 15,263,154
*	Fidelity Advisor Freedom® 2040 Fund Class Z6	Mutual Funds	5,771,686
	BlackRock Equity Dividend Fund K Shares	Mutual Funds	4,764,533
*	Fidelity Advisor Freedom® 2050 Fund Class Z6	Mutual Funds	4,560,101
*	Fidelity Advisor Freedom® 2035 Fund Class Z6	Mutual Funds	6,535,708
	BlackRock LifePath® Index 2045 Fund Class K Shares	Mutual Funds	6,468,155
*	Fidelity Advisor Freedom® 2045 Fund Class Z6	Mutual Funds	4,948,140
	BlackRock LifePath® Index 2050 Fund Class K Shares	Mutual Funds	6,857,534
	BlackRock LifePath® Index 2055 Fund Class K Shares	Mutual Funds	5,840,933
	BlackRock LifePath® Index 2040 Fund Class K Shares	Mutual Funds	5,462,427
*	Fidelity Advisor Freedom® 2030 Fund Class Z6	Mutual Funds	2,986,805
*	Fidelity Advisor® Strategic Income Fund Class Z	Mutual Funds	2,272,409
*	Fidelity® International Index Fund	Mutual Funds	2,403,691
*	Fidelity® Mid Cap Index Fund	Mutual Funds	2,576,245
	LifePath Index 2060 Fund	Mutual Funds	4,426,489
*	Fidelity Advisor® Investment Grade Bond Fund Class Z	Mutual Funds	1,414,287
	American Century Mid Cap Value Fund R6 Class	Mutual Funds	1,885,539
*	Fidelity Advisor Freedom® 2055 Fund Class Z6	Mutual Funds	2,230,916
	JPMorgan Core Bond Fund Class R6	Mutual Funds	2,150,181
	JPMorgan Mid Cap Growth Fund Class R6	Mutual Funds	1,545,094
	AB Small Cap Growth Portfolio Class Z	Mutual Funds	1,959,591
	MFS New Discovery Value Fund Class R6	Mutual Funds	1,771,331
	MFS International Growth Fund Class R6	Mutual Funds	2,358,614
	BlackRock LifePath® Index 2035 Fund Class K Shares	Mutual Funds	3,002,868
*	Fidelity Advisor Freedom® 2025 Fund Class Z6	Mutual Funds	925,644
*	Fidelity® Small Cap Index Fund	Mutual Funds	1,520,898
	BlackRock LifePath® Index 2030 Fund Class K Shares	Mutual Funds	2,088,469
*	Fidelity ® Government Money Market Fund Class K6	Mutual Funds	1,326,614
*	Fidelity Advisor Freedom® 2020 Fund Class Z6	Mutual Funds	731,046
*	Fidelity Advisor Freedom® 2010 Fund Class Z6	Mutual Funds	449,344
*	Fidelity Advisor® International Small Cap Fund Class Z	Mutual Funds	446,633
*	Fidelity Advisor Freedom® 2060 Fund Class Z6	Mutual Funds	462,200
*	Fidelity Advisor Freedom® Income Fund Class Z6	Mutual Funds	187,195
*	Fidelity Advisor Freedom® 2015 Fund Class Z6	Mutual Funds	140,737
	BlackRock LifePath® Index Retirement Fund Class K Shares	Mutual Funds	1,268,533
	LifePath Index 2065 Fund	Mutual Funds	397,237
*	Fidelity Advisor Freedom® 2065 Fund Class Z6	Mutual Funds	127,056
*	JPMorgan Large Cap Growth Fund Class R6	Mutual Funds	9,403,594
*	Fidelity Advisor® Emerging Markets Fund Class Z	Mutual Funds	658,154
*	Fidelity Advisor® Capital & Income Fund Class Z	Mutual Funds	1,385,683

**American Society of Clinical Oncology  
401(k) Profit Sharing Plan  
EIN: 13-6180380  
Plan # 001**

**Schedule of Assets (Held at End of Year) (Schedule H, Line 4i)  
December 31, 2024**

(a)	(b) Identity of issuer, borrower, lessor or similar party	(c) Description of Investment including Maturity Date, Rate of Interest, Collateral, Par or Maturity Value	(e) Current Value
	Guaranteed investment contract:		
*	Fidelity Advisor Stable Value Portfolio Class I	Guaranteed Investment contract	2,594,090
	Total investments, at fair value		123,569,558
*	Notes receivable from participants	Interest rates ranging from 4.25% to 9.50%, maturing at various dates, secured by participant account balance	98,628
	Total investments		<u>\$ 123,668,186</u>

\* Represents a party-in-interest as defined by ERISA.

Note: The cost of participant-directed investments is not required to be disclosed.

See Independent Auditor's Report.



**Independent Member of Nexia**

**[cohnreznick.com](http://cohnreznick.com)**